drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00283 | DB11160 | 701 | 337 | [
"DDInter395",
"DDInter1459"
] | Clemastine | Phenyltoloxamine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. Phenyltoloxamine acts as an adjuvant analgesic, which augments the analgesic effect of acetaminophen. It also potentiates the effects of other drugs, such as codeine and codeine derivatives. Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain barrier and causing tranquilizing effects at CNS histamine receptors, many of the drug's specific pharmacokinetics are not readily available - perhaps also because many early (phenyltoloxamine was involved in studies as early as the 1950s) first-generation antihistamines were not optimally investigated . Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient. | Moderate | 1 | [
[
[
701,
24,
337
]
],
[
[
701,
23,
771
],
[
771,
62,
337
]
],
[
[
701,
24,
820
],
[
820,
24,
337
]
],
[
[
701,
35,
1594
],
[
1594,
24,
337
]
],
[
[
701,
63,
352
],
[
352,
24,
337
]
],
[
[
701,
24,
1609
],
[
1609,
63,
337
]
],
[
[
701,
25,
1621
],
[
1621,
25,
337
]
],
[
[
701,
23,
771
],
[
771,
62,
820
],
[
820,
24,
337
]
],
[
[
701,
24,
820
],
[
820,
23,
771
],
[
771,
62,
337
]
],
[
[
701,
24,
999
],
[
999,
63,
1594
],
[
1594,
24,
337
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
]
] | Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Clemastine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Phenyltoloxamine
Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine |
DB00443 | DB14711 | 251 | 779 | [
"DDInter195",
"DDInter1680"
] | Betamethasone | Smallpox (Vaccinia) Vaccine, Live | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
251,
25,
779
]
],
[
[
251,
64,
1064
],
[
1064,
25,
779
]
],
[
[
251,
24,
478
],
[
478,
25,
779
]
],
[
[
251,
25,
1377
],
[
1377,
25,
779
]
],
[
[
251,
63,
1560
],
[
1560,
25,
779
]
],
[
[
251,
1,
1220
],
[
1220,
25,
779
]
],
[
[
251,
25,
676
],
[
676,
64,
779
]
],
[
[
251,
40,
870
],
[
870,
25,
779
]
],
[
[
251,
64,
1064
],
[
1064,
25,
478
],
[
478,
25,
779
]
],
[
[
251,
24,
478
],
[
478,
64,
1064
],
[
1064,
25,
779
]
]
] | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
]
] | Betamethasone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live |
DB00418 | DB06228 | 536 | 792 | [
"DDInter1650",
"DDInter1609"
] | Secobarbital | Rivaroxaban | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Moderate | 1 | [
[
[
536,
24,
792
]
],
[
[
536,
21,
28769
],
[
28769,
60,
792
]
],
[
[
536,
23,
752
],
[
752,
24,
792
]
],
[
[
536,
63,
79
],
[
79,
24,
792
]
],
[
[
536,
24,
466
],
[
466,
63,
792
]
],
[
[
536,
24,
597
],
[
597,
24,
792
]
],
[
[
536,
62,
1101
],
[
1101,
24,
792
]
],
[
[
536,
25,
765
],
[
765,
24,
792
]
],
[
[
536,
40,
288
],
[
288,
24,
792
]
],
[
[
536,
24,
129
],
[
129,
64,
792
]
]
] | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
]
] | Secobarbital (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Rivaroxaban (Compound)
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Secobarbital may lead to a major life threatening interaction when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Secobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Rivaroxaban |
DB01010 | DB01041 | 61 | 770 | [
"DDInter622",
"DDInter1789"
] | Edrophonium | Thalidomide | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
61,
24,
770
]
],
[
[
61,
21,
28892
],
[
28892,
60,
770
]
],
[
[
61,
24,
1401
],
[
1401,
24,
770
]
],
[
[
61,
63,
494
],
[
494,
24,
770
]
],
[
[
61,
24,
667
],
[
667,
63,
770
]
],
[
[
61,
1,
768
],
[
768,
63,
770
]
],
[
[
61,
63,
695
],
[
695,
25,
770
]
],
[
[
61,
24,
1220
],
[
1220,
64,
770
]
],
[
[
61,
21,
28892
],
[
28892,
60,
1668
],
[
1668,
1,
770
]
],
[
[
61,
21,
28751
],
[
28751,
60,
609
],
[
609,
63,
770
]
]
] | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
],
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} (Compound) resembles {v} (Compound)",
"Tapentadol"
],
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} (Compound) resembles {v} (Compound)",
"Thalidomide"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
]
] | Edrophonium (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Thalidomide (Compound)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin and Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Edrophonium (Compound) resembles Tapentadol (Compound) and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Thalidomide
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Thalidomide
Edrophonium (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Thalidomide (Compound)
Edrophonium (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide |
DB00912 | DB06663 | 473 | 1,154 | [
"DDInter1581",
"DDInter1398"
] | Repaglinide | Pasireotide | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
473,
24,
1154
]
],
[
[
473,
63,
966
],
[
966,
40,
1154
]
],
[
[
473,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
473,
24,
1247
],
[
1247,
23,
1154
]
],
[
[
473,
24,
466
],
[
466,
62,
1154
]
],
[
[
473,
24,
1385
],
[
1385,
63,
1154
]
],
[
[
473,
63,
88
],
[
88,
24,
1154
]
],
[
[
473,
24,
699
],
[
699,
24,
1154
]
],
[
[
473,
64,
839
],
[
839,
25,
1154
]
],
[
[
473,
63,
600
],
[
600,
25,
1154
]
]
] | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
]
] | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Repaglinide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Repaglinide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Pasireotide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Pasireotide |
DB00491 | DB00717 | 127 | 1,197 | [
"DDInter1217",
"DDInter1312"
] | Miglitol | Norethisterone | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962. | Moderate | 1 | [
[
[
127,
24,
1197
]
],
[
[
127,
24,
984
],
[
984,
40,
1197
]
],
[
[
127,
24,
167
],
[
167,
1,
1197
]
],
[
[
127,
63,
989
],
[
989,
1,
1197
]
],
[
[
127,
63,
566
],
[
566,
40,
1197
]
],
[
[
127,
21,
28900
],
[
28900,
60,
1197
]
],
[
[
127,
24,
609
],
[
609,
63,
1197
]
],
[
[
127,
63,
590
],
[
590,
24,
1197
]
],
[
[
127,
24,
1040
],
[
1040,
64,
1197
]
],
[
[
127,
24,
984
],
[
984,
40,
890
],
[
890,
1,
1197
]
]
] | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
],
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norethisterone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
],
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
]
]
] | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Norethisterone (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Norethisterone (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Norethisterone (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Norethisterone (Compound)
Miglitol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Norethisterone (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Norethisterone
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Mestranol (Compound) and Mestranol (Compound) resembles Norethisterone (Compound) |
DB00686 | DB09079 | 383 | 1,496 | [
"DDInter1424",
"DDInter1296"
] | Pentosan polysulfate | Nintedanib | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options. | Moderate | 1 | [
[
[
383,
24,
1496
]
],
[
[
383,
24,
707
],
[
707,
24,
1496
]
],
[
[
383,
63,
20
],
[
20,
24,
1496
]
],
[
[
383,
24,
1421
],
[
1421,
63,
1496
]
],
[
[
383,
63,
834
],
[
834,
25,
1496
]
],
[
[
383,
24,
707
],
[
707,
64,
20
],
[
20,
24,
1496
]
],
[
[
383,
63,
20
],
[
20,
25,
707
],
[
707,
24,
1496
]
],
[
[
383,
24,
1317
],
[
1317,
25,
707
],
[
707,
24,
1496
]
],
[
[
383,
24,
765
],
[
765,
63,
20
],
[
20,
24,
1496
]
],
[
[
383,
63,
25
],
[
25,
24,
1317
],
[
1317,
24,
1496
]
]
] | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
]
] | Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid and Danaparoid may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib |
DB00405 | DB01181 | 128 | 1,532 | [
"DDInter517",
"DDInter906"
] | Dexbrompheniramine | Ifosfamide | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
128,
24,
1532
]
],
[
[
128,
24,
684
],
[
684,
24,
1532
]
],
[
[
128,
24,
481
],
[
481,
63,
1532
]
],
[
[
128,
63,
1315
],
[
1315,
24,
1532
]
],
[
[
128,
74,
1594
],
[
1594,
24,
1532
]
],
[
[
128,
25,
675
],
[
675,
24,
1532
]
],
[
[
128,
63,
695
],
[
695,
25,
1532
]
],
[
[
128,
24,
770
],
[
770,
25,
1532
]
],
[
[
128,
24,
684
],
[
684,
6,
3486
],
[
3486,
45,
1532
]
],
[
[
128,
24,
1170
],
[
1170,
21,
28956
],
[
28956,
60,
1532
]
]
] | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorzoxazone"
],
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amantadine"
],
[
"Amantadine",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ifosfamide"
]
]
] | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone and Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Dexbrompheniramine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Ifosfamide
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ifosfamide (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Amantadine and Amantadine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound) |
DB00635 | DB00963 | 1,573 | 1,263 | [
"DDInter1515",
"DDInter241"
] | Prednisone | Bromfenac | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] | Moderate | 1 | [
[
[
1573,
24,
1263
]
],
[
[
1573,
24,
935
],
[
935,
40,
1263
]
],
[
[
1573,
63,
831
],
[
831,
40,
1263
]
],
[
[
1573,
63,
1512
],
[
1512,
24,
1263
]
],
[
[
1573,
21,
28847
],
[
28847,
60,
1263
]
],
[
[
1573,
23,
115
],
[
115,
62,
1263
]
],
[
[
1573,
40,
167
],
[
167,
24,
1263
]
],
[
[
1573,
24,
1479
],
[
1479,
24,
1263
]
],
[
[
1573,
24,
123
],
[
123,
63,
1263
]
],
[
[
1573,
62,
1018
],
[
1018,
24,
1263
]
]
] | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} (Compound) resembles {v} (Compound)",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
]
] | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Bromfenac (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisone (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Bromfenac (Compound)
Prednisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Bromfenac
Prednisone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac |
DB01246 | DB08903 | 820 | 996 | [
"DDInter45",
"DDInter170"
] | Alimemazine | Bedaquiline | A phenothiazine derivative that is used as an antipruritic. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Major | 2 | [
[
[
820,
25,
996
]
],
[
[
820,
40,
649
],
[
649,
1,
996
]
],
[
[
820,
74,
1376
],
[
1376,
1,
996
]
],
[
[
820,
63,
358
],
[
358,
40,
996
]
],
[
[
820,
6,
8374
],
[
8374,
45,
996
]
],
[
[
820,
21,
29282
],
[
29282,
60,
996
]
],
[
[
820,
62,
112
],
[
112,
23,
996
]
],
[
[
820,
64,
593
],
[
593,
24,
996
]
],
[
[
820,
63,
355
],
[
355,
24,
996
]
],
[
[
820,
24,
144
],
[
144,
63,
996
]
]
] | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} (Compound) causes {v} (Side Effect)",
"Arrhythmia"
],
[
"Arrhythmia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
]
] | Alimemazine (Compound) resembles Clofedanol (Compound) and Clofedanol (Compound) resembles Bedaquiline (Compound)
Alimemazine (Compound) resembles Diphenhydramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Bedaquiline (Compound)
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Bedaquiline (Compound)
Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Alimemazine (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Alimemazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline |
DB06702 | DB12500 | 573 | 283 | [
"DDInter731",
"DDInter714"
] | Fesoterodine | Fedratinib | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
573,
24,
283
]
],
[
[
573,
24,
351
],
[
351,
23,
283
]
],
[
[
573,
63,
1419
],
[
1419,
24,
283
]
],
[
[
573,
40,
211
],
[
211,
24,
283
]
],
[
[
573,
24,
98
],
[
98,
24,
283
]
],
[
[
573,
24,
159
],
[
159,
63,
283
]
],
[
[
573,
24,
1017
],
[
1017,
25,
283
]
],
[
[
573,
25,
384
],
[
384,
25,
283
]
],
[
[
573,
63,
1220
],
[
1220,
25,
283
]
],
[
[
573,
64,
609
],
[
609,
25,
283
]
]
] | [
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Fesoterodine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fesoterodine (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib
Fesoterodine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Fedratinib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Fedratinib
Fesoterodine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fedratinib |
DB00916 | DB01246 | 112 | 820 | [
"DDInter1202",
"DDInter45"
] | Metronidazole | Alimemazine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | A phenothiazine derivative that is used as an antipruritic. | Minor | 0 | [
[
[
112,
23,
820
]
],
[
[
112,
23,
401
],
[
401,
24,
820
]
],
[
[
112,
63,
1236
],
[
1236,
24,
820
]
],
[
[
112,
62,
675
],
[
675,
25,
820
]
],
[
[
112,
62,
508
],
[
508,
1,
820
]
],
[
[
112,
23,
9
],
[
9,
1,
820
]
],
[
[
112,
6,
8374
],
[
8374,
45,
820
]
],
[
[
112,
21,
28662
],
[
28662,
60,
820
]
],
[
[
112,
23,
1247
],
[
1247,
23,
820
]
],
[
[
112,
62,
252
],
[
252,
24,
820
]
]
] | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alimemazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
]
] | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Alimemazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Promazine and Promazine (Compound) resembles Alimemazine (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Alimemazine (Compound)
Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Metronidazole (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Alimemazine (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Alimemazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine |
DB00529 | DB06788 | 789 | 1,616 | [
"DDInter779",
"DDInter864"
] | Foscarnet | Histrelin | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Moderate | 1 | [
[
[
789,
24,
1616
]
],
[
[
789,
23,
112
],
[
112,
23,
1616
]
],
[
[
789,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
789,
24,
603
],
[
603,
63,
1616
]
],
[
[
789,
63,
600
],
[
600,
24,
1616
]
],
[
[
789,
25,
1487
],
[
1487,
24,
1616
]
],
[
[
789,
25,
57
],
[
57,
25,
1616
]
],
[
[
789,
25,
868
],
[
868,
64,
1616
]
],
[
[
789,
64,
702
],
[
702,
25,
1616
]
],
[
[
789,
23,
112
],
[
112,
23,
1247
],
[
1247,
23,
1616
]
]
] | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Foscarnet",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Histrelin"
]
]
] | Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Foscarnet may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Foscarnet may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin
Foscarnet may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Histrelin
Foscarnet may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Histrelin
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Histrelin |
DB00694 | DB05273 | 51 | 507 | [
"DDInter485",
"DDInter1638"
] | Daunorubicin | Samarium (153Sm) lexidronam | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. | Major | 2 | [
[
[
51,
25,
507
]
],
[
[
51,
63,
789
],
[
789,
24,
507
]
],
[
[
51,
24,
248
],
[
248,
24,
507
]
],
[
[
51,
24,
270
],
[
270,
63,
507
]
],
[
[
51,
63,
970
],
[
970,
25,
507
]
],
[
[
51,
24,
1686
],
[
1686,
25,
507
]
],
[
[
51,
35,
77
],
[
77,
25,
507
]
],
[
[
51,
25,
39
],
[
39,
64,
507
]
],
[
[
51,
24,
1468
],
[
1468,
64,
507
]
],
[
[
51,
64,
1064
],
[
1064,
25,
507
]
]
] | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
],
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
]
] | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Daunorubicin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Daunorubicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam |
DB00975 | DB10672 | 1,317 | 297 | [
"DDInter573",
"DDInter417"
] | Dipyridamole | Clove | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1317,
23,
297
]
],
[
[
1317,
25,
235
],
[
235,
62,
297
]
],
[
[
1317,
24,
578
],
[
578,
23,
297
]
],
[
[
1317,
25,
1564
],
[
1564,
23,
297
]
],
[
[
1317,
64,
366
],
[
366,
23,
297
]
],
[
[
1317,
63,
582
],
[
582,
23,
297
]
],
[
[
1317,
25,
235
],
[
235,
63,
578
],
[
578,
23,
297
]
],
[
[
1317,
24,
578
],
[
578,
24,
235
],
[
235,
62,
297
]
],
[
[
1317,
25,
1564
],
[
1564,
25,
235
],
[
235,
62,
297
]
],
[
[
1317,
64,
366
],
[
366,
25,
235
],
[
235,
62,
297
]
]
] | [
[
[
"Dipyridamole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
]
] | Dipyridamole may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Dipyridamole may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove |
DB00812 | DB01067 | 998 | 959 | [
"DDInter1451",
"DDInter826"
] | Phenylbutazone | Glipizide | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822) | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. | Moderate | 1 | [
[
[
998,
24,
959
]
],
[
[
998,
63,
245
],
[
245,
40,
959
]
],
[
[
998,
24,
1411
],
[
1411,
1,
959
]
],
[
[
998,
6,
8374
],
[
8374,
45,
959
]
],
[
[
998,
24,
1220
],
[
1220,
63,
959
]
],
[
[
998,
24,
1479
],
[
1479,
24,
959
]
],
[
[
998,
64,
126
],
[
126,
24,
959
]
],
[
[
998,
63,
50
],
[
50,
24,
959
]
],
[
[
998,
62,
1101
],
[
1101,
24,
959
]
],
[
[
998,
1,
804
],
[
804,
63,
959
]
]
] | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfinpyrazone"
],
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
]
] | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Phenylbutazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glipizide (Compound)
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Phenylbutazone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide |
DB00620 | DB00976 | 175 | 1,056 | [
"DDInter1855",
"DDInter1758"
] | Triamcinolone | Telithromycin | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Major | 2 | [
[
[
175,
25,
1056
]
],
[
[
175,
6,
8374
],
[
8374,
45,
1056
]
],
[
[
175,
21,
28681
],
[
28681,
60,
1056
]
],
[
[
175,
40,
1220
],
[
1220,
63,
1056
]
],
[
[
175,
63,
663
],
[
663,
24,
1056
]
],
[
[
175,
40,
870
],
[
870,
24,
1056
]
],
[
[
175,
24,
473
],
[
473,
24,
1056
]
],
[
[
175,
23,
688
],
[
688,
63,
1056
]
],
[
[
175,
25,
760
],
[
760,
63,
1056
]
],
[
[
175,
24,
98
],
[
98,
63,
1056
]
]
] | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
]
] | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Triamcinolone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Telithromycin (Compound)
Triamcinolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Triamcinolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Triamcinolone may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin |
DB00366 | DB11915 | 1,594 | 1,293 | [
"DDInter600",
"DDInter1909"
] | Doxylamine | Valbenazine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg. | Moderate | 1 | [
[
[
1594,
24,
1293
]
],
[
[
1594,
24,
516
],
[
516,
24,
1293
]
],
[
[
1594,
63,
1242
],
[
1242,
24,
1293
]
],
[
[
1594,
74,
701
],
[
701,
24,
1293
]
],
[
[
1594,
40,
888
],
[
888,
24,
1293
]
],
[
[
1594,
35,
272
],
[
272,
24,
1293
]
],
[
[
1594,
25,
1053
],
[
1053,
25,
1293
]
],
[
[
1594,
40,
11
],
[
11,
25,
1293
]
],
[
[
1594,
24,
516
],
[
516,
63,
401
],
[
401,
24,
1293
]
],
[
[
1594,
24,
401
],
[
401,
62,
112
],
[
112,
23,
1293
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Valbenazine"
]
]
] | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Doxylamine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Doxylamine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Valbenazine
Doxylamine (Compound) resembles Toremifene (Compound) and Toremifene may lead to a major life threatening interaction when taken with Valbenazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine |
DB00046 | DB00307 | 1,179 | 1,101 | [
"DDInter940",
"DDInter202"
] | Insulin lispro | Bexarotene | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Moderate | 1 | [
[
[
1179,
24,
1101
]
],
[
[
1179,
24,
609
],
[
609,
62,
1101
]
],
[
[
1179,
24,
362
],
[
362,
23,
1101
]
],
[
[
1179,
25,
839
],
[
839,
62,
1101
]
],
[
[
1179,
24,
915
],
[
915,
63,
1101
]
],
[
[
1179,
24,
215
],
[
215,
24,
1101
]
],
[
[
1179,
24,
1206
],
[
1206,
64,
1101
]
],
[
[
1179,
63,
305
],
[
305,
25,
1101
]
],
[
[
1179,
25,
1299
],
[
1299,
64,
1101
]
],
[
[
1179,
24,
1560
],
[
1560,
25,
1101
]
]
] | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
],
[
"Gemfibrozil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
]
] | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Insulin lispro may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may lead to a major life threatening interaction when taken with Bexarotene
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Bexarotene
Insulin lispro may lead to a major life threatening interaction when taken with Trovafloxacin and Trovafloxacin may lead to a major life threatening interaction when taken with Bexarotene
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene |
DB00631 | DB01033 | 372 | 328 | [
"DDInter405",
"DDInter1156"
] | Clofarabine | Mercaptopurine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
372,
24,
328
]
],
[
[
372,
5,
11555
],
[
11555,
44,
328
]
],
[
[
372,
21,
29662
],
[
29662,
60,
328
]
],
[
[
372,
24,
1299
],
[
1299,
23,
328
]
],
[
[
372,
63,
663
],
[
663,
23,
328
]
],
[
[
372,
23,
945
],
[
945,
62,
328
]
],
[
[
372,
23,
739
],
[
739,
23,
328
]
],
[
[
372,
62,
839
],
[
839,
23,
328
]
],
[
[
372,
63,
1257
],
[
1257,
24,
328
]
],
[
[
372,
24,
1627
],
[
1627,
63,
328
]
]
] | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Candida infection"
],
[
"Candida infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
]
] | Clofarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Mercaptopurine (Compound)
Clofarabine (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Mercaptopurine (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine |
DB00515 | DB08904 | 589 | 375 | [
"DDInter387",
"DDInter342"
] | Cisplatin | Certolizumab pegol | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
589,
25,
375
]
],
[
[
589,
63,
1461
],
[
1461,
23,
375
]
],
[
[
589,
24,
231
],
[
231,
24,
375
]
],
[
[
589,
24,
200
],
[
200,
63,
375
]
],
[
[
589,
63,
66
],
[
66,
24,
375
]
],
[
[
589,
25,
33
],
[
33,
24,
375
]
],
[
[
589,
64,
1066
],
[
1066,
25,
375
]
],
[
[
589,
24,
870
],
[
870,
25,
375
]
],
[
[
589,
63,
552
],
[
552,
25,
375
]
],
[
[
589,
24,
1330
],
[
1330,
64,
375
]
]
] | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
],
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cisplatin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cisplatin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may lead to a major life threatening interaction when taken with Certolizumab pegol
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Certolizumab pegol
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB06016 | DB09073 | 1,508 | 951 | [
"DDInter300",
"DDInter1379"
] | Cariprazine | Palbociclib | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Moderate | 1 | [
[
[
1508,
24,
951
]
],
[
[
1508,
24,
159
],
[
159,
63,
951
]
],
[
[
1508,
63,
600
],
[
600,
24,
951
]
],
[
[
1508,
24,
578
],
[
578,
24,
951
]
],
[
[
1508,
24,
129
],
[
129,
25,
951
]
],
[
[
1508,
64,
609
],
[
609,
25,
951
]
],
[
[
1508,
24,
913
],
[
913,
64,
951
]
],
[
[
1508,
25,
760
],
[
760,
25,
951
]
],
[
[
1508,
24,
159
],
[
159,
62,
907
],
[
907,
62,
951
]
],
[
[
1508,
24,
351
],
[
351,
23,
907
],
[
907,
62,
951
]
]
] | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
]
] | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Palbociclib
Cariprazine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Palbociclib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Palbociclib
Cariprazine may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Palbociclib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib |
DB01166 | DB01242 | 477 | 1,237 | [
"DDInter379",
"DDInter410"
] | Cilostazol | Clomipramine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. | Moderate | 1 | [
[
[
477,
24,
1237
]
],
[
[
477,
64,
684
],
[
684,
1,
1237
]
],
[
[
477,
63,
1164
],
[
1164,
1,
1237
]
],
[
[
477,
63,
401
],
[
401,
24,
1237
]
],
[
[
477,
24,
9
],
[
9,
1,
1237
]
],
[
[
477,
24,
820
],
[
820,
63,
1237
]
],
[
[
477,
6,
7950
],
[
7950,
45,
1237
]
],
[
[
477,
21,
28703
],
[
28703,
60,
1237
]
],
[
[
477,
62,
112
],
[
112,
23,
1237
]
],
[
[
477,
64,
1578
],
[
1578,
24,
1237
]
]
] | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clomipramine"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
]
] | Cilostazol may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Clomipramine (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Cilostazol (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Clomipramine (Compound)
Cilostazol (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Clomipramine (Compound)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clomipramine
Cilostazol may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine |
DB00014 | DB06288 | 521 | 607 | [
"DDInter839",
"DDInter77"
] | Goserelin | Amisulpride | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys. | Major | 2 | [
[
[
521,
25,
607
]
],
[
[
521,
21,
29232
],
[
29232,
60,
607
]
],
[
[
521,
23,
112
],
[
112,
23,
607
]
],
[
[
521,
24,
1559
],
[
1559,
24,
607
]
],
[
[
521,
24,
1383
],
[
1383,
63,
607
]
],
[
[
521,
25,
351
],
[
351,
64,
607
]
],
[
[
521,
24,
401
],
[
401,
25,
607
]
],
[
[
521,
25,
1166
],
[
1166,
25,
607
]
],
[
[
521,
24,
823
],
[
823,
64,
607
]
],
[
[
521,
1,
774
],
[
774,
64,
607
]
]
] | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
],
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
]
] | Goserelin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Goserelin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Amisulpride
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Amisulpride
Goserelin may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Amisulpride
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may lead to a major life threatening interaction when taken with Amisulpride
Goserelin (Compound) resembles Degarelix (Compound) and Degarelix may lead to a major life threatening interaction when taken with Amisulpride |
DB00026 | DB09052 | 1,184 | 250 | [
"DDInter94",
"DDInter220"
] | Anakinra | Blinatumomab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. In March 2018, it was approved under the FDA’s accelerated approval program for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Full approval for this indication was granted in June 2023.[L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery. | Moderate | 1 | [
[
[
1184,
24,
250
]
],
[
[
1184,
24,
949
],
[
949,
63,
250
]
],
[
[
1184,
63,
305
],
[
305,
24,
250
]
],
[
[
1184,
24,
1236
],
[
1236,
24,
250
]
],
[
[
1184,
25,
581
],
[
581,
25,
250
]
],
[
[
1184,
64,
1057
],
[
1057,
25,
250
]
],
[
[
1184,
25,
1137
],
[
1137,
64,
250
]
],
[
[
1184,
24,
949
],
[
949,
63,
1362
],
[
1362,
63,
250
]
],
[
[
1184,
24,
1362
],
[
1362,
24,
949
],
[
949,
63,
250
]
],
[
[
1184,
63,
305
],
[
305,
24,
949
],
[
949,
63,
250
]
]
] | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
]
] | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Anakinra may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Blinatumomab
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Blinatumomab
Anakinra may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Blinatumomab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab |
DB01133 | DB01592 | 1,104 | 1,596 | [
"DDInter1808",
"DDInter975"
] | Tiludronic acid | Iron | Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone. Tiludronic acid was granted FDA approval on 7 March 1997. | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. | Moderate | 1 | [
[
[
1104,
24,
1596
]
],
[
[
1104,
21,
28810
],
[
28810,
60,
1596
]
],
[
[
1104,
24,
1193
],
[
1193,
62,
1596
]
],
[
[
1104,
24,
1283
],
[
1283,
24,
1596
]
],
[
[
1104,
24,
286
],
[
286,
63,
1596
]
],
[
[
1104,
21,
28810
],
[
28810,
60,
1096
],
[
1096,
23,
1596
]
],
[
[
1104,
24,
1193
],
[
1193,
62,
1096
],
[
1096,
23,
1596
]
],
[
[
1104,
24,
489
],
[
489,
63,
964
],
[
964,
24,
1596
]
],
[
[
1104,
24,
1606
],
[
1606,
63,
1096
],
[
1096,
23,
1596
]
],
[
[
1104,
5,
11658
],
[
11658,
44,
1485
],
[
1485,
24,
1596
]
]
] | [
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
],
[
"Iron sucrose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Tiludronic acid",
"{u} (Compound) treats {v} (Disease)",
"Paget's disease of bone"
],
[
"Paget's disease of bone",
"{u} (Disease) is treated by {v} (Compound)",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
]
] | Tiludronic acid (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Iron (Compound)
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Iron
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Iron
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Iron
Tiludronic acid (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
sucrose and Iron sucrose may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Iron
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
Tiludronic acid (Compound) treats Paget's disease of bone (Disease) and Paget's disease of bone (Disease) is treated by Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Iron |
DB04946 | DB09054 | 924 | 384 | [
"DDInter907",
"DDInter905"
] | Iloperidone | Idelalisib | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Major | 2 | [
[
[
924,
25,
384
]
],
[
[
924,
63,
222
],
[
222,
23,
384
]
],
[
[
924,
25,
1618
],
[
1618,
24,
384
]
],
[
[
924,
64,
888
],
[
888,
24,
384
]
],
[
[
924,
25,
1228
],
[
1228,
63,
384
]
],
[
[
924,
24,
761
],
[
761,
24,
384
]
],
[
[
924,
63,
1648
],
[
1648,
24,
384
]
],
[
[
924,
24,
659
],
[
659,
63,
384
]
],
[
[
924,
40,
883
],
[
883,
24,
384
]
],
[
[
924,
25,
594
],
[
594,
25,
384
]
]
] | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} (Compound) resembles {v} (Compound)",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
]
] | Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Iloperidone may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Iloperidone may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Iloperidone may lead to a major life threatening interaction when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Iloperidone (Compound) resembles Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Iloperidone may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Idelalisib |
DB00703 | DB01124 | 997 | 1,411 | [
"DDInter1167",
"DDInter1828"
] | Methazolamide | Tolbutamide | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
997,
24,
1411
]
],
[
[
997,
24,
959
],
[
959,
40,
1411
]
],
[
[
997,
63,
245
],
[
245,
40,
1411
]
],
[
[
997,
6,
10215
],
[
10215,
45,
1411
]
],
[
[
997,
21,
28828
],
[
28828,
60,
1411
]
],
[
[
997,
24,
1296
],
[
1296,
63,
1411
]
],
[
[
997,
40,
471
],
[
471,
24,
1411
]
],
[
[
997,
24,
480
],
[
480,
24,
1411
]
],
[
[
997,
63,
251
],
[
251,
24,
1411
]
],
[
[
997,
25,
1479
],
[
1479,
24,
1411
]
]
] | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Methazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
]
] | Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Methazolamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Methazolamide (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Tolbutamide (Compound)
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Methazolamide (Compound) resembles Acetazolamide (Compound) and Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Methazolamide may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB00241 | DB00877 | 288 | 629 | [
"DDInter257",
"DDInter1678"
] | Butalbital | Sirolimus | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex. | Moderate | 1 | [
[
[
288,
24,
629
]
],
[
[
288,
24,
1476
],
[
1476,
63,
629
]
],
[
[
288,
24,
167
],
[
167,
24,
629
]
],
[
[
288,
23,
752
],
[
752,
24,
629
]
],
[
[
288,
40,
1023
],
[
1023,
24,
629
]
],
[
[
288,
1,
536
],
[
536,
24,
629
]
],
[
[
288,
24,
384
],
[
384,
64,
629
]
],
[
[
288,
24,
1476
],
[
1476,
24,
907
],
[
907,
62,
629
]
],
[
[
288,
24,
1311
],
[
1311,
21,
28979
],
[
28979,
60,
629
]
],
[
[
288,
24,
167
],
[
167,
6,
4973
],
[
4973,
45,
629
]
]
] | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) causes {v} (Side Effect)",
"Asthma"
],
[
"Asthma",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"
]
]
] | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Butalbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Sirolimus
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Sirolimus
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) causes Asthma (Side Effect) and Asthma (Side Effect) is caused by Sirolimus (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound) |
DB00945 | DB00991 | 1,479 | 97 | [
"DDInter20",
"DDInter1358"
] | Acetylsalicylic acid | Oxaprozin | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others. Acetylsalicylic acid is a very common | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
1479,
24,
97
]
],
[
[
1479,
62,
362
],
[
362,
1,
97
]
],
[
[
1479,
63,
1274
],
[
1274,
24,
97
]
],
[
[
1479,
63,
998
],
[
998,
1,
97
]
],
[
[
1479,
6,
10522
],
[
10522,
45,
97
]
],
[
[
1479,
10,
11577
],
[
11577,
49,
97
]
],
[
[
1479,
54,
19122
],
[
19122,
15,
97
]
],
[
[
1479,
21,
28744
],
[
28744,
60,
97
]
],
[
[
1479,
24,
1486
],
[
1486,
24,
97
]
],
[
[
1479,
25,
1047
],
[
1047,
63,
97
]
]
] | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) palliates {v} (Disease)",
"rheumatoid arthritis"
],
[
"rheumatoid arthritis",
"{u} (Disease) is palliated by {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Nonsteroidal Anti-inflammatory Compounds"
],
[
"Nonsteroidal Anti-inflammatory Compounds",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Deafness"
],
[
"Deafness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
]
] | Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Phenytoin and Phenytoin (Compound) resembles Oxaprozin (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Oxaprozin (Compound)
Acetylsalicylic acid (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Oxaprozin (Compound)
Acetylsalicylic acid (Compound) palliates rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Oxaprozin (Compound)
Acetylsalicylic acid (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Oxaprozin (Compound)
Acetylsalicylic acid (Compound) causes Deafness (Side Effect) and Deafness (Side Effect) is caused by Oxaprozin (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin |
DB00586 | DB08895 | 1,512 | 976 | [
"DDInter537",
"DDInter1825"
] | Diclofenac | Tofacitinib | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Moderate | 1 | [
[
[
1512,
24,
976
]
],
[
[
1512,
23,
307
],
[
307,
23,
976
]
],
[
[
1512,
24,
214
],
[
214,
63,
976
]
],
[
[
1512,
24,
86
],
[
86,
24,
976
]
],
[
[
1512,
40,
1020
],
[
1020,
24,
976
]
],
[
[
1512,
63,
1027
],
[
1027,
24,
976
]
],
[
[
1512,
1,
1364
],
[
1364,
24,
976
]
],
[
[
1512,
23,
479
],
[
479,
24,
976
]
],
[
[
1512,
35,
1338
],
[
1338,
24,
976
]
],
[
[
1512,
64,
886
],
[
886,
24,
976
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
],
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Guanfacine"
],
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
],
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
]
] | Diclofenac may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diclofenac (Compound) resembles Clonidine (Compound) and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diclofenac (Compound) resembles Guanfacine (Compound) and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diclofenac may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib |
DB00773 | DB04868 | 896 | 478 | [
"DDInter702",
"DDInter1293"
] | Etoposide | Nilotinib | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
896,
24,
478
]
],
[
[
896,
24,
1468
],
[
1468,
63,
478
]
],
[
[
896,
5,
11555
],
[
11555,
44,
478
]
],
[
[
896,
6,
15705
],
[
15705,
45,
478
]
],
[
[
896,
7,
6865
],
[
6865,
46,
478
]
],
[
[
896,
18,
2183
],
[
2183,
57,
478
]
],
[
[
896,
33,
3199
],
[
3199,
57,
478
]
],
[
[
896,
21,
28762
],
[
28762,
60,
478
]
],
[
[
896,
62,
307
],
[
307,
23,
478
]
],
[
[
896,
24,
112
],
[
112,
23,
478
]
]
] | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"ICAM1"
],
[
"ICAM1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
]
] | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Etoposide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Etoposide (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Nilotinib (Compound)
Etoposide (Compound) upregulates ICAM1 (Gene) and ICAM1 (Gene) is upregulated by Nilotinib (Compound)
Etoposide (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Etoposide (Compound) binds TOP2A (Gene) and Etoposide (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is downregulated by Nilotinib (Compound)
Etoposide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib |
DB00214 | DB01276 | 1,028 | 123 | [
"DDInter1836",
"DDInter706"
] | Torasemide | Exenatide | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Moderate | 1 | [
[
[
1028,
24,
123
]
],
[
[
1028,
24,
708
],
[
708,
63,
123
]
],
[
[
1028,
24,
1573
],
[
1573,
24,
123
]
],
[
[
1028,
63,
1685
],
[
1685,
24,
123
]
],
[
[
1028,
25,
361
],
[
361,
24,
123
]
],
[
[
1028,
24,
708
],
[
708,
63,
380
],
[
380,
24,
123
]
],
[
[
1028,
24,
1573
],
[
1573,
63,
1252
],
[
1252,
23,
123
]
],
[
[
1028,
63,
1685
],
[
1685,
23,
1103
],
[
1103,
23,
123
]
],
[
[
1028,
24,
1254
],
[
1254,
62,
1103
],
[
1103,
23,
123
]
],
[
[
1028,
25,
361
],
[
361,
62,
1252
],
[
1252,
23,
123
]
]
] | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
]
] | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Torasemide may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide
Torasemide may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide |
DB01222 | DB14783 | 617 | 287 | [
"DDInter246",
"DDInter574"
] | Budesonide | Diroximel fumarate | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
617,
24,
287
]
],
[
[
617,
63,
1560
],
[
1560,
24,
287
]
],
[
[
617,
25,
384
],
[
384,
24,
287
]
],
[
[
617,
40,
1220
],
[
1220,
24,
287
]
],
[
[
617,
24,
1619
],
[
1619,
24,
287
]
],
[
[
617,
25,
1510
],
[
1510,
25,
287
]
],
[
[
617,
64,
1066
],
[
1066,
25,
287
]
],
[
[
617,
25,
676
],
[
676,
64,
287
]
],
[
[
617,
24,
713
],
[
713,
25,
287
]
],
[
[
617,
63,
1560
],
[
1560,
25,
1101
],
[
1101,
24,
287
]
]
] | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
] | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Budesonide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Budesonide (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Budesonide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Budesonide may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Budesonide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB00445 | DB00563 | 322 | 663 | [
"DDInter655",
"DDInter1174"
] | Epirubicin | Methotrexate | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Moderate | 1 | [
[
[
322,
24,
663
]
],
[
[
322,
5,
11616
],
[
11616,
44,
663
]
],
[
[
322,
6,
10417
],
[
10417,
45,
663
]
],
[
[
322,
7,
14544
],
[
14544,
45,
663
]
],
[
[
322,
7,
2903
],
[
2903,
46,
663
]
],
[
[
322,
18,
2309
],
[
2309,
46,
663
]
],
[
[
322,
18,
2199
],
[
2199,
57,
663
]
],
[
[
322,
33,
3199
],
[
3199,
57,
663
]
],
[
[
322,
21,
29215
],
[
29215,
60,
663
]
],
[
[
322,
24,
328
],
[
328,
62,
663
]
]
] | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) treats {v} (Disease)",
"stomach cancer"
],
[
"stomach cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"ABCC10"
],
[
"ABCC10",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"MMP1"
],
[
"MMP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"BRCA1"
],
[
"BRCA1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"RAN"
],
[
"RAN",
"{u} (Gene) is downregulated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Ecchymosis"
],
[
"Ecchymosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrexate"
]
]
] | Epirubicin (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Methotrexate (Compound)
Epirubicin (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Methotrexate (Compound)
Epirubicin (Compound) upregulates ABCC10 (Gene) and ABCC10 (Gene) is bound by Methotrexate (Compound)
Epirubicin (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Methotrexate (Compound)
Epirubicin (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is upregulated by Methotrexate (Compound)
Epirubicin (Compound) downregulates RAN (Gene) and RAN (Gene) is downregulated by Methotrexate (Compound)
Epirubicin (Compound) binds TOP2A (Gene) and Epirubicin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is downregulated by Methotrexate (Compound)
Epirubicin (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Methotrexate (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Methotrexate |
DB00704 | DB06777 | 267 | 780 | [
"DDInter1263",
"DDInter348"
] | Naltrexone | Chenodeoxycholic acid | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated. | Moderate | 1 | [
[
[
267,
24,
780
]
],
[
[
267,
21,
28890
],
[
28890,
60,
780
]
],
[
[
267,
24,
384
],
[
384,
63,
780
]
],
[
[
267,
63,
372
],
[
372,
24,
780
]
],
[
[
267,
24,
535
],
[
535,
24,
780
]
],
[
[
267,
25,
1510
],
[
1510,
64,
780
]
],
[
[
267,
25,
1070
],
[
1070,
25,
780
]
],
[
[
267,
21,
28890
],
[
28890,
60,
906
],
[
906,
1,
780
]
],
[
[
267,
24,
384
],
[
384,
24,
1534
],
[
1534,
63,
780
]
],
[
[
267,
24,
1534
],
[
1534,
63,
384
],
[
384,
63,
780
]
]
] | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial infarction"
],
[
"Myocardial infarction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
],
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
],
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial infarction"
],
[
"Myocardial infarction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ursodeoxycholic acid"
],
[
"Ursodeoxycholic acid",
"{u} (Compound) resembles {v} (Compound)",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibric acid"
],
[
"Fenofibric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibric acid"
],
[
"Fenofibric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
]
] | Naltrexone (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Chenodeoxycholic acid (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibrate and Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid
Naltrexone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Chenodeoxycholic acid
Naltrexone may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Chenodeoxycholic acid
Naltrexone (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Ursodeoxycholic acid (Compound) and Ursodeoxycholic acid (Compound) resembles Chenodeoxycholic acid (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid and Fenofibric acid may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid and Fenofibric acid may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid |
DB00674 | DB00748 | 1,516 | 662 | [
"DDInter802",
"DDInter297"
] | Galantamine | Carbinoxamine | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Moderate | 1 | [
[
[
1516,
24,
662
]
],
[
[
1516,
63,
1594
],
[
1594,
24,
662
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
662
]
],
[
[
1516,
18,
15501
],
[
15501,
57,
662
]
],
[
[
1516,
21,
28921
],
[
28921,
60,
662
]
],
[
[
1516,
24,
830
],
[
830,
63,
662
]
],
[
[
1516,
1,
828
],
[
828,
24,
662
]
],
[
[
1516,
24,
1442
],
[
1442,
24,
662
]
],
[
[
1516,
24,
832
],
[
832,
74,
662
]
],
[
[
1516,
63,
1594
],
[
1594,
35,
128
],
[
128,
24,
662
]
]
] | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
]
] | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Carbinoxamine (Compound)
Galantamine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Carbinoxamine (Compound)
Galantamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Carbinoxamine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Galantamine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Carbinoxamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine |
DB00697 | DB06699 | 876 | 774 | [
"DDInter1821",
"DDInter493"
] | Tizanidine | Degarelix | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
876,
24,
774
]
],
[
[
876,
63,
521
],
[
521,
1,
774
]
],
[
[
876,
21,
29232
],
[
29232,
60,
774
]
],
[
[
876,
23,
112
],
[
112,
23,
774
]
],
[
[
876,
63,
888
],
[
888,
24,
774
]
],
[
[
876,
24,
484
],
[
484,
63,
774
]
],
[
[
876,
24,
455
],
[
455,
24,
774
]
],
[
[
876,
25,
1559
],
[
1559,
24,
774
]
],
[
[
876,
25,
1619
],
[
1619,
63,
774
]
],
[
[
876,
25,
877
],
[
877,
64,
774
]
]
] | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
]
] | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Tizanidine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Tizanidine may lead to a major life threatening interaction when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Tizanidine may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Tizanidine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Degarelix |
DB00277 | DB00549 | 1,031 | 522 | [
"DDInter1791",
"DDInter1955"
] | Theophylline | Zafirlukast | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Moderate | 1 | [
[
[
1031,
24,
522
]
],
[
[
1031,
5,
11649
],
[
11649,
44,
522
]
],
[
[
1031,
6,
7950
],
[
7950,
45,
522
]
],
[
[
1031,
21,
28698
],
[
28698,
60,
522
]
],
[
[
1031,
63,
491
],
[
491,
24,
522
]
],
[
[
1031,
24,
1362
],
[
1362,
63,
522
]
],
[
[
1031,
23,
915
],
[
915,
63,
522
]
],
[
[
1031,
24,
1510
],
[
1510,
64,
522
]
],
[
[
1031,
5,
11649
],
[
11649,
9,
16521
],
[
16521,
45,
522
]
],
[
[
1031,
6,
7950
],
[
7950,
45,
1230
],
[
1230,
23,
522
]
]
] | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} (Compound) treats {v} (Disease)",
"asthma"
],
[
"asthma",
"{u} (Disease) is treated by {v} (Compound)",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} (Compound) treats {v} (Disease)",
"asthma"
],
[
"asthma",
"{u} (Disease) is associated with {v} (Gene)",
"CYSLTR2"
],
[
"CYSLTR2",
"{u} (Gene) is bound by {v} (Compound)",
"Zafirlukast"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
]
]
] | Theophylline (Compound) treats asthma (Disease) and asthma (Disease) is treated by Zafirlukast (Compound)
Theophylline (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Zafirlukast (Compound)
Theophylline (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Zafirlukast (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Theophylline may cause a minor interaction that can limit clinical effects when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Zafirlukast
Theophylline (Compound) treats asthma (Disease) and asthma (Disease) is associated with CYSLTR2 (Gene) and CYSLTR2 (Gene) is bound by Zafirlukast (Compound)
Theophylline (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Zafirlukast |
DB01234 | DB06717 | 1,220 | 875 | [
"DDInter513",
"DDInter778"
] | Dexamethasone | Fosaprepitant | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
1220,
24,
875
]
],
[
[
1220,
63,
723
],
[
723,
1,
875
]
],
[
[
1220,
21,
28757
],
[
28757,
60,
875
]
],
[
[
1220,
25,
466
],
[
466,
62,
875
]
],
[
[
1220,
63,
1101
],
[
1101,
23,
875
]
],
[
[
1220,
24,
760
],
[
760,
63,
875
]
],
[
[
1220,
62,
608
],
[
608,
24,
875
]
],
[
[
1220,
63,
473
],
[
473,
24,
875
]
],
[
[
1220,
1,
175
],
[
175,
24,
875
]
],
[
[
1220,
24,
761
],
[
761,
24,
875
]
]
] | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} (Compound) resembles {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
]
] | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Dexamethasone (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Fosaprepitant (Compound)
Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Dexamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant |
DB00317 | DB01097 | 883 | 1,377 | [
"DDInter810",
"DDInter1033"
] | Gefitinib | Leflunomide | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
883,
25,
1377
]
],
[
[
883,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
883,
7,
9489
],
[
9489,
46,
1377
]
],
[
[
883,
18,
2049
],
[
2049,
57,
1377
]
],
[
[
883,
21,
29231
],
[
29231,
60,
1377
]
],
[
[
883,
24,
242
],
[
242,
63,
1377
]
],
[
[
883,
24,
126
],
[
126,
24,
1377
]
],
[
[
883,
24,
1622
],
[
1622,
25,
1377
]
],
[
[
883,
24,
996
],
[
996,
64,
1377
]
],
[
[
883,
35,
392
],
[
392,
64,
1377
]
]
] | [
[
[
"Gefitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} (Compound) upregulates {v} (Gene)",
"WIF1"
],
[
"WIF1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} (Compound) downregulates {v} (Gene)",
"MRPS16"
],
[
"MRPS16",
"{u} (Gene) is downregulated by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
]
] | Gefitinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Gefitinib (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Leflunomide (Compound)
Gefitinib (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Leflunomide (Compound)
Gefitinib (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Leflunomide (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may lead to a major life threatening interaction when taken with Leflunomide
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may lead to a major life threatening interaction when taken with Leflunomide
Gefitinib (Compound) resembles Lapatinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Leflunomide |
DB00334 | DB08899 | 867 | 129 | [
"DDInter1326",
"DDInter649"
] | Olanzapine | Enzalutamide | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
867,
24,
129
]
],
[
[
867,
24,
918
],
[
918,
1,
129
]
],
[
[
867,
6,
8374
],
[
8374,
45,
129
]
],
[
[
867,
23,
112
],
[
112,
23,
129
]
],
[
[
867,
24,
1510
],
[
1510,
24,
129
]
],
[
[
867,
24,
659
],
[
659,
63,
129
]
],
[
[
867,
63,
600
],
[
600,
24,
129
]
],
[
[
867,
1,
87
],
[
87,
24,
129
]
],
[
[
867,
24,
351
],
[
351,
64,
129
]
],
[
[
867,
24,
1011
],
[
1011,
25,
129
]
]
] | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
]
] | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Olanzapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Enzalutamide
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Enzalutamide |
DB01276 | DB01404 | 123 | 757 | [
"DDInter706",
"DDInter820"
] | Exenatide | Ginseng | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
123,
24,
757
]
],
[
[
123,
63,
245
],
[
245,
24,
757
]
],
[
[
123,
24,
1254
],
[
1254,
24,
757
]
],
[
[
123,
24,
1296
],
[
1296,
63,
757
]
],
[
[
123,
63,
245
],
[
245,
24,
170
],
[
170,
24,
757
]
],
[
[
123,
63,
1144
],
[
1144,
63,
245
],
[
245,
24,
757
]
],
[
[
123,
24,
1254
],
[
1254,
63,
245
],
[
245,
24,
757
]
],
[
[
123,
63,
1411
],
[
1411,
1,
245
],
[
245,
24,
757
]
],
[
[
123,
62,
1103
],
[
1103,
62,
245
],
[
245,
24,
757
]
],
[
[
123,
63,
245
],
[
245,
24,
1344
],
[
1344,
63,
757
]
]
] | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
]
] | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ginseng |
DB00790 | DB11921 | 664 | 1,019 | [
"DDInter1431",
"DDInter492"
] | Perindopril | Deflazacort | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
664,
24,
1019
]
],
[
[
664,
24,
959
],
[
959,
24,
1019
]
],
[
[
664,
23,
286
],
[
286,
24,
1019
]
],
[
[
664,
63,
1512
],
[
1512,
24,
1019
]
],
[
[
664,
40,
1058
],
[
1058,
24,
1019
]
],
[
[
664,
1,
954
],
[
954,
24,
1019
]
],
[
[
664,
24,
1220
],
[
1220,
25,
1019
]
],
[
[
664,
25,
1510
],
[
1510,
25,
1019
]
],
[
[
664,
24,
959
],
[
959,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
664,
24,
629
],
[
629,
23,
1193
],
[
1193,
23,
1019
]
]
] | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
]
] | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Perindopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Perindopril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort
Perindopril may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Deflazacort
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort |
DB00475 | DB04837 | 1,119 | 649 | [
"DDInter355",
"DDInter407"
] | Chlordiazepoxide | Clofedanol | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1119,
24,
649
]
],
[
[
1119,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1119,
1,
11275
],
[
11275,
40,
649
]
],
[
[
1119,
24,
832
],
[
832,
40,
649
]
],
[
[
1119,
63,
701
],
[
701,
24,
649
]
],
[
[
1119,
1,
902
],
[
902,
24,
649
]
],
[
[
1119,
40,
1382
],
[
1382,
24,
649
]
],
[
[
1119,
24,
1609
],
[
1609,
63,
649
]
],
[
[
1119,
64,
475
],
[
475,
24,
649
]
],
[
[
1119,
24,
662
],
[
662,
35,
649
]
]
] | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
]
] | Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlordiazepoxide (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Clofedanol (Compound)
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Clofedanol (Compound)
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlordiazepoxide (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlordiazepoxide (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlordiazepoxide may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol |
DB12500 | DB13179 | 283 | 68 | [
"DDInter714",
"DDInter1882"
] | Fedratinib | Troleandomycin | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
283,
25,
68
]
],
[
[
283,
63,
1601
],
[
1601,
23,
68
]
],
[
[
283,
23,
466
],
[
466,
23,
68
]
],
[
[
283,
63,
309
],
[
309,
24,
68
]
],
[
[
283,
64,
1220
],
[
1220,
24,
68
]
],
[
[
283,
63,
1618
],
[
1618,
25,
68
]
],
[
[
283,
62,
1593
],
[
1593,
25,
68
]
],
[
[
283,
64,
840
],
[
840,
25,
68
]
],
[
[
283,
24,
159
],
[
159,
64,
68
]
],
[
[
283,
63,
1601
],
[
1601,
24,
1619
],
[
1619,
24,
68
]
]
] | [
[
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loratadine"
],
[
"Loratadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loratadine"
],
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
]
] | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Fedratinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Troleandomycin
Fedratinib may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may lead to a major life threatening interaction when taken with Troleandomycin
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead to a major life threatening interaction when taken with Troleandomycin
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin |
DB00683 | DB08899 | 1,382 | 129 | [
"DDInter1212",
"DDInter649"
] | Midazolam | Enzalutamide | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019 | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
1382,
24,
129
]
],
[
[
1382,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1382,
21,
28703
],
[
28703,
60,
129
]
],
[
[
1382,
63,
608
],
[
608,
23,
129
]
],
[
[
1382,
24,
1040
],
[
1040,
63,
129
]
],
[
[
1382,
23,
286
],
[
286,
63,
129
]
],
[
[
1382,
63,
1101
],
[
1101,
24,
129
]
],
[
[
1382,
24,
1532
],
[
1532,
24,
129
]
],
[
[
1382,
64,
600
],
[
600,
24,
129
]
],
[
[
1382,
1,
1565
],
[
1565,
24,
129
]
]
] | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] | Midazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Midazolam (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Midazolam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Midazolam may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Midazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB00782 | DB00843 | 1,123 | 479 | [
"DDInter1535",
"DDInter583"
] | Propantheline | Donepezil | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia. | Moderate | 1 | [
[
[
1123,
24,
479
]
],
[
[
1123,
21,
28817
],
[
28817,
60,
479
]
],
[
[
1123,
63,
1442
],
[
1442,
24,
479
]
],
[
[
1123,
24,
104
],
[
104,
63,
479
]
],
[
[
1123,
24,
543
],
[
543,
24,
479
]
],
[
[
1123,
21,
28817
],
[
28817,
60,
1433
],
[
1433,
40,
479
]
],
[
[
1123,
21,
29356
],
[
29356,
60,
723
],
[
723,
23,
479
]
],
[
[
1123,
21,
28671
],
[
28671,
60,
843
],
[
843,
1,
479
]
],
[
[
1123,
63,
1442
],
[
1442,
21,
28741
],
[
28741,
60,
479
]
],
[
[
1123,
63,
1425
],
[
1425,
25,
843
],
[
843,
1,
479
]
]
] | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxazosin"
],
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} (Compound) causes {v} (Side Effect)",
"Salivary hypersecretion"
],
[
"Salivary hypersecretion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} (Compound) causes {v} (Side Effect)",
"Dysphagia"
],
[
"Dysphagia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} (Compound) resembles {v} (Compound)",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Donepezil"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} (Compound) resembles {v} (Compound)",
"Donepezil"
]
]
] | Propantheline (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Donepezil (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil
Propantheline (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Doxazosin (Compound) and Doxazosin (Compound) resembles Donepezil (Compound)
Propantheline (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Donepezil
Propantheline (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Tetrabenazine (Compound) and Tetrabenazine (Compound) resembles Donepezil (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Donepezil (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound) |
DB01004 | DB01206 | 563 | 37 | [
"DDInter806",
"DDInter1086"
] | Ganciclovir | Lomustine | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
563,
24,
37
]
],
[
[
563,
21,
28675
],
[
28675,
60,
37
]
],
[
[
563,
63,
147
],
[
147,
23,
37
]
],
[
[
563,
63,
141
],
[
141,
24,
37
]
],
[
[
563,
24,
384
],
[
384,
63,
37
]
],
[
[
563,
24,
328
],
[
328,
24,
37
]
],
[
[
563,
1,
248
],
[
248,
63,
37
]
],
[
[
563,
25,
375
],
[
375,
64,
37
]
],
[
[
563,
24,
1377
],
[
1377,
25,
37
]
],
[
[
563,
24,
976
],
[
976,
64,
37
]
]
] | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Visual impairment"
],
[
"Visual impairment",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
]
] | Ganciclovir (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Lomustine (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Ganciclovir (Compound) resembles Valganciclovir (Compound) and Val
Ganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Lomustine
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Lomustine
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Lomustine |
DB00206 | DB00860 | 1,245 | 891 | [
"DDInter1582",
"DDInter1513"
] | Reserpine | Prednisolone | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. The FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1245,
24,
891
]
],
[
[
1245,
24,
175
],
[
175,
40,
891
]
],
[
[
1245,
24,
167
],
[
167,
1,
891
]
],
[
[
1245,
6,
4973
],
[
4973,
45,
891
]
],
[
[
1245,
7,
3163
],
[
3163,
46,
891
]
],
[
[
1245,
18,
17469
],
[
17469,
57,
891
]
],
[
[
1245,
21,
29544
],
[
29544,
60,
891
]
],
[
[
1245,
24,
1148
],
[
1148,
62,
891
]
],
[
[
1245,
40,
1340
],
[
1340,
63,
891
]
],
[
[
1245,
24,
549
],
[
549,
63,
891
]
]
] | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} (Compound) downregulates {v} (Gene)",
"ADI1"
],
[
"ADI1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} (Compound) causes {v} (Side Effect)",
"Weight increased"
],
[
"Weight increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} (Compound) resembles {v} (Compound)",
"Deserpidine"
],
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
]
] | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Prednisolone (Compound)
Reserpine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Prednisolone (Compound)
Reserpine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Prednisolone (Compound)
Reserpine (Compound) downregulates ADI1 (Gene) and ADI1 (Gene) is downregulated by Prednisolone (Compound)
Reserpine (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Prednisolone (Compound)
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Prednisolone
Reserpine (Compound) resembles Deserpidine (Compound) and Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone |
DB00748 | DB00986 | 662 | 1,192 | [
"DDInter297",
"DDInter834"
] | Carbinoxamine | Glycopyrronium | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. Glycopyrronium was originally granted FDA approval on 11 August 1961. | Moderate | 1 | [
[
[
662,
24,
1192
]
],
[
[
662,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
662,
24,
262
],
[
262,
24,
1192
]
],
[
[
662,
21,
28817
],
[
28817,
60,
1192
]
],
[
[
662,
24,
551
],
[
551,
23,
1192
]
],
[
[
662,
63,
475
],
[
475,
24,
1192
]
],
[
[
662,
35,
1376
],
[
1376,
63,
1192
]
],
[
[
662,
35,
832
],
[
832,
24,
1192
]
],
[
[
662,
64,
675
],
[
675,
24,
1192
]
],
[
[
662,
25,
1621
],
[
1621,
25,
1192
]
]
] | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Carbinoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glycopyrronium"
]
]
] | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Carbinoxamine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Glycopyrronium (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Carbinoxamine (Compound) resembles Tripelennamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Carbinoxamine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Carbinoxamine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Glycopyrronium |
DB06616 | DB09104 | 594 | 286 | [
"DDInter224",
"DDInter1118"
] | Bosutinib | Magnesium hydroxide | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
594,
24,
286
]
],
[
[
594,
63,
820
],
[
820,
23,
286
]
],
[
[
594,
24,
1468
],
[
1468,
23,
286
]
],
[
[
594,
64,
859
],
[
859,
24,
286
]
],
[
[
594,
63,
633
],
[
633,
24,
286
]
],
[
[
594,
25,
1593
],
[
1593,
24,
286
]
],
[
[
594,
24,
730
],
[
730,
63,
286
]
],
[
[
594,
25,
982
],
[
982,
63,
286
]
],
[
[
594,
24,
786
],
[
786,
24,
286
]
],
[
[
594,
75,
1069
],
[
1069,
24,
286
]
]
] | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
],
[
"Deutetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bosutinib",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
]
] | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Bosutinib may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Bosutinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Bosutinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Bosutinib (Compound) resembles Vandetanib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide |
DB00631 | DB08865 | 372 | 1,593 | [
"DDInter405",
"DDInter448"
] | Clofarabine | Crizotinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
372,
24,
1593
]
],
[
[
372,
7,
5295
],
[
5295,
45,
1593
]
],
[
[
372,
7,
2900
],
[
2900,
46,
1593
]
],
[
[
372,
18,
13042
],
[
13042,
46,
1593
]
],
[
[
372,
18,
17859
],
[
17859,
57,
1593
]
],
[
[
372,
7,
4071
],
[
4071,
57,
1593
]
],
[
[
372,
6,
2104
],
[
2104,
57,
1593
]
],
[
[
372,
21,
28771
],
[
28771,
60,
1593
]
],
[
[
372,
24,
283
],
[
283,
62,
1593
]
],
[
[
372,
24,
1247
],
[
1247,
23,
1593
]
]
] | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"CDK7"
],
[
"CDK7",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} (Compound) downregulates {v} (Gene)",
"HIST1H2BK"
],
[
"HIST1H2BK",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} (Compound) downregulates {v} (Gene)",
"KIF18B"
],
[
"KIF18B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"PNP"
],
[
"PNP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} (Compound) binds {v} (Gene)",
"POLA1"
],
[
"POLA1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Respiratory failure"
],
[
"Respiratory failure",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
]
] | Clofarabine (Compound) upregulates CDK7 (Gene) and CDK7 (Gene) is bound by Crizotinib (Compound)
Clofarabine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Crizotinib (Compound)
Clofarabine (Compound) downregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Crizotinib (Compound)
Clofarabine (Compound) downregulates KIF18B (Gene) and KIF18B (Gene) is downregulated by Crizotinib (Compound)
Clofarabine (Compound) upregulates PNP (Gene) and PNP (Gene) is downregulated by Crizotinib (Compound)
Clofarabine (Compound) binds POLA1 (Gene) and POLA1 (Gene) is downregulated by Crizotinib (Compound)
Clofarabine (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Crizotinib |
DB00604 | DB01035 | 1,425 | 1,401 | [
"DDInter385",
"DDInter1524"
] | Cisapride | Procainamide | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | A derivative of procaine with less CNS action. | Major | 2 | [
[
[
1425,
25,
1401
]
],
[
[
1425,
40,
1311
],
[
1311,
63,
1401
]
],
[
[
1425,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
1425,
23,
112
],
[
112,
23,
1401
]
],
[
[
1425,
24,
770
],
[
770,
63,
1401
]
],
[
[
1425,
23,
1194
],
[
1194,
24,
1401
]
],
[
[
1425,
24,
480
],
[
480,
24,
1401
]
],
[
[
1425,
64,
752
],
[
752,
24,
1401
]
],
[
[
1425,
63,
355
],
[
355,
24,
1401
]
],
[
[
1425,
25,
982
],
[
982,
64,
1401
]
]
] | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} (Compound) resembles {v} (Compound)",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
]
] | Cisapride (Compound) resembles Metoclopramide (Compound) and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Cisapride (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Procainamide
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Cisapride may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Cisapride may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Cisapride may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Procainamide |
DB00555 | DB11186 | 706 | 1,609 | [
"DDInter1020",
"DDInter1427"
] | Lamotrigine | Pentoxyverine | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850] | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Moderate | 1 | [
[
[
706,
24,
1609
]
],
[
[
706,
24,
649
],
[
649,
24,
1609
]
],
[
[
706,
63,
506
],
[
506,
24,
1609
]
],
[
[
706,
24,
649
],
[
649,
63,
314
],
[
314,
24,
1609
]
],
[
[
706,
63,
506
],
[
506,
24,
314
],
[
314,
24,
1609
]
],
[
[
706,
24,
662
],
[
662,
24,
314
],
[
314,
24,
1609
]
],
[
[
706,
63,
475
],
[
475,
25,
314
],
[
314,
24,
1609
]
],
[
[
706,
24,
407
],
[
407,
64,
314
],
[
314,
24,
1609
]
],
[
[
706,
7,
4830
],
[
4830,
46,
314
],
[
314,
24,
1609
]
],
[
[
706,
63,
506
],
[
506,
63,
556
],
[
556,
24,
1609
]
]
] | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} (Compound) upregulates {v} (Gene)",
"TGFBR2"
],
[
"TGFBR2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
]
] | Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may lead to a major life threatening interaction when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine (Compound) upregulates TGFBR2 (Gene) and TGFBR2 (Gene) is upregulated by Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB00647 | DB06663 | 675 | 1,154 | [
"DDInter528",
"DDInter1398"
] | Dextropropoxyphene | Pasireotide | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
675,
25,
1154
]
],
[
[
675,
63,
1314
],
[
1314,
40,
1154
]
],
[
[
675,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
675,
23,
112
],
[
112,
23,
1154
]
],
[
[
675,
24,
959
],
[
959,
24,
1154
]
],
[
[
675,
24,
1662
],
[
1662,
63,
1154
]
],
[
[
675,
63,
355
],
[
355,
24,
1154
]
],
[
[
675,
25,
770
],
[
770,
24,
1154
]
],
[
[
675,
64,
702
],
[
702,
25,
1154
]
],
[
[
675,
63,
1494
],
[
1494,
25,
1154
]
]
] | [
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
]
] | Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Pasireotide (Compound)
Dextropropoxyphene (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Dextropropoxyphene may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Dextropropoxyphene may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Pasireotide
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Pasireotide |
DB00682 | DB08873 | 126 | 74 | [
"DDInter1951",
"DDInter221"
] | Warfarin | Boceprevir | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed. | Moderate | 1 | [
[
[
126,
24,
74
]
],
[
[
126,
6,
8374
],
[
8374,
45,
74
]
],
[
[
126,
24,
1496
],
[
1496,
63,
74
]
],
[
[
126,
63,
1424
],
[
1424,
24,
74
]
],
[
[
126,
25,
86
],
[
86,
24,
74
]
],
[
[
126,
24,
1220
],
[
1220,
24,
74
]
],
[
[
126,
64,
1419
],
[
1419,
24,
74
]
],
[
[
126,
25,
1421
],
[
1421,
63,
74
]
],
[
[
126,
62,
168
],
[
168,
24,
74
]
],
[
[
126,
25,
1409
],
[
1409,
25,
74
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
]
] | Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Warfarin may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Warfarin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Warfarin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Warfarin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Boceprevir |
DB00853 | DB01097 | 1,686 | 1,377 | [
"DDInter1762",
"DDInter1033"
] | Temozolomide | Leflunomide | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1686,
25,
1377
]
],
[
[
1686,
18,
4930
],
[
4930,
57,
1377
]
],
[
[
1686,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
1686,
63,
1461
],
[
1461,
23,
1377
]
],
[
[
1686,
24,
949
],
[
949,
63,
1377
]
],
[
[
1686,
24,
563
],
[
563,
24,
1377
]
],
[
[
1686,
63,
597
],
[
597,
24,
1377
]
],
[
[
1686,
24,
996
],
[
996,
64,
1377
]
],
[
[
1686,
63,
66
],
[
66,
25,
1377
]
],
[
[
1686,
25,
779
],
[
779,
64,
1377
]
]
] | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
]
] | Temozolomide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Leflunomide (Compound)
Temozolomide (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may lead to a major life threatening interaction when taken with Leflunomide
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may lead to a major life threatening interaction when taken with Leflunomide
Temozolomide may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Leflunomide |
DB00717 | DB06203 | 1,197 | 1,002 | [
"DDInter1312",
"DDInter51"
] | Norethisterone | Alogliptin | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Moderate | 1 | [
[
[
1197,
24,
1002
]
],
[
[
1197,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1197,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
1197,
21,
28778
],
[
28778,
60,
1002
]
],
[
[
1197,
63,
176
],
[
176,
24,
1002
]
],
[
[
1197,
1,
35
],
[
35,
24,
1002
]
],
[
[
1197,
24,
629
],
[
629,
24,
1002
]
],
[
[
1197,
40,
1657
],
[
1657,
24,
1002
]
],
[
[
1197,
24,
1296
],
[
1296,
63,
1002
]
],
[
[
1197,
25,
1476
],
[
1476,
63,
1002
]
]
] | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
],
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Desogestrel"
],
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
]
] | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Norethisterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Norethisterone (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Alogliptin (Compound)
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Norethisterone (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Norethisterone (Compound) resembles Desogestrel (Compound) and Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Norethisterone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin |
DB00467 | DB01024 | 1,467 | 1,096 | [
"DDInter644",
"DDInter1252"
] | Enoxacin | Mycophenolic acid | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. [Mycophenolate mofetil], a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection. | Moderate | 1 | [
[
[
1467,
24,
1096
]
],
[
[
1467,
7,
5415
],
[
5415,
46,
1096
]
],
[
[
1467,
7,
5178
],
[
5178,
57,
1096
]
],
[
[
1467,
24,
1193
],
[
1193,
62,
1096
]
],
[
[
1467,
64,
1031
],
[
1031,
23,
1096
]
],
[
[
1467,
24,
965
],
[
965,
24,
1096
]
],
[
[
1467,
24,
286
],
[
286,
63,
1096
]
],
[
[
1467,
1,
1539
],
[
1539,
63,
1096
]
],
[
[
1467,
40,
739
],
[
739,
24,
1096
]
],
[
[
1467,
40,
246
],
[
246,
63,
1096
]
]
] | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} (Compound) upregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} (Compound) upregulates {v} (Gene)",
"XBP1"
],
[
"XBP1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevelamer"
],
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
]
] | Enoxacin (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Mycophenolic acid (Compound)
Enoxacin (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Mycophenolic acid (Compound)
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Enoxacin may lead to a major life threatening interaction when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Sevelamer and Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Enoxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Enoxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Enoxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid |
DB00771 | DB01069 | 262 | 401 | [
"DDInter397",
"DDInter1533"
] | Clidinium | Promethazine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
262,
24,
401
]
],
[
[
262,
24,
146
],
[
146,
24,
401
]
],
[
[
262,
24,
1264
],
[
1264,
63,
401
]
],
[
[
262,
40,
11392
],
[
11392,
40,
401
]
],
[
[
262,
6,
2720
],
[
2720,
45,
401
]
],
[
[
262,
63,
677
],
[
677,
24,
401
]
],
[
[
262,
23,
504
],
[
504,
24,
401
]
],
[
[
262,
74,
352
],
[
352,
24,
401
]
],
[
[
262,
62,
811
],
[
811,
24,
401
]
],
[
[
262,
23,
178
],
[
178,
63,
401
]
]
] | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl Acetate"
],
[
"Methadyl Acetate",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Botulinum toxin type A"
],
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clidinium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
]
] | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Clidinium (Compound) resembles Methadyl Acetate (Compound) and Methadyl Acetate (Compound) resembles Promethazine (Compound)
Clidinium (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Promethazine (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Botulinum toxin type A and Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Clidinium may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Clidinium (Compound) resembles Trospium (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Clidinium may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Clidinium may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00501 | DB00857 | 752 | 1,387 | [
"DDInter380",
"DDInter1768"
] | Cimetidine | Terbinafine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992. | Minor | 0 | [
[
[
752,
23,
1387
]
],
[
[
752,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
752,
18,
8954
],
[
8954,
57,
1387
]
],
[
[
752,
21,
28822
],
[
28822,
60,
1387
]
],
[
[
752,
24,
479
],
[
479,
23,
1387
]
],
[
[
752,
24,
211
],
[
211,
62,
1387
]
],
[
[
752,
62,
1684
],
[
1684,
23,
1387
]
],
[
[
752,
64,
1181
],
[
1181,
23,
1387
]
],
[
[
752,
25,
915
],
[
915,
62,
1387
]
],
[
[
752,
63,
109
],
[
109,
24,
1387
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} (Compound) downregulates {v} (Gene)",
"HACD3"
],
[
"HACD3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Alopecia"
],
[
"Alopecia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Caffeine"
],
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
]
] | Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Cimetidine (Compound) downregulates HACD3 (Gene) and HACD3 (Gene) is downregulated by Terbinafine (Compound)
Cimetidine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Terbinafine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Terbinafine
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Terbinafine
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Caffeine and Caffeine may cause a minor interaction that can limit clinical effects when taken with Terbinafine
Cimetidine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a minor interaction that can limit clinical effects when taken with Terbinafine
Cimetidine may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a minor interaction that can limit clinical effects when taken with Terbinafine
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Terbinafine |
DB00374 | DB00393 | 1,061 | 854 | [
"DDInter1852",
"DDInter1295"
] | Treprostinil | Nimodipine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. | Moderate | 1 | [
[
[
1061,
24,
854
]
],
[
[
1061,
24,
84
],
[
84,
40,
854
]
],
[
[
1061,
63,
1428
],
[
1428,
40,
854
]
],
[
[
1061,
21,
29118
],
[
29118,
60,
854
]
],
[
[
1061,
24,
578
],
[
578,
62,
854
]
],
[
[
1061,
24,
1040
],
[
1040,
63,
854
]
],
[
[
1061,
25,
1213
],
[
1213,
63,
854
]
],
[
[
1061,
1,
885
],
[
885,
63,
854
]
],
[
[
1061,
24,
1604
],
[
1604,
64,
854
]
],
[
[
1061,
24,
84
],
[
84,
1,
11502
],
[
11502,
40,
854
]
]
] | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nimodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
],
[
"Nitrendipine",
"{u} (Compound) resembles {v} (Compound)",
"Nimodipine"
]
]
] | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine (Compound) resembles Nimodipine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nimodipine (Compound)
Treprostinil (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Nimodipine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nimodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine
Treprostinil may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Nimodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine (Compound) resembles Nitrendipine (Compound) and Nitrendipine (Compound) resembles Nimodipine (Compound) |
DB08873 | DB11691 | 74 | 1,499 | [
"DDInter221",
"DDInter1258"
] | Boceprevir | Naldemedine | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Moderate | 1 | [
[
[
74,
24,
1499
]
],
[
[
74,
63,
723
],
[
723,
24,
1499
]
],
[
[
74,
25,
1670
],
[
1670,
24,
1499
]
],
[
[
74,
25,
1406
],
[
1406,
63,
1499
]
],
[
[
74,
64,
1478
],
[
1478,
24,
1499
]
],
[
[
74,
24,
1040
],
[
1040,
24,
1499
]
],
[
[
74,
24,
1619
],
[
1619,
63,
1499
]
],
[
[
74,
25,
129
],
[
129,
25,
1499
]
],
[
[
74,
25,
913
],
[
913,
64,
1499
]
],
[
[
74,
63,
723
],
[
723,
23,
307
],
[
307,
23,
1499
]
]
] | [
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naldemedine"
]
]
] | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Boceprevir may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Boceprevir may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Boceprevir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Boceprevir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Naldemedine
Boceprevir may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Naldemedine
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine |
DB01254 | DB09330 | 1,213 | 985 | [
"DDInter484",
"DDInter1352"
] | Dasatinib | Osimertinib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
1213,
25,
985
]
],
[
[
1213,
62,
1247
],
[
1247,
23,
985
]
],
[
[
1213,
63,
608
],
[
608,
23,
985
]
],
[
[
1213,
24,
1478
],
[
1478,
24,
985
]
],
[
[
1213,
63,
66
],
[
66,
24,
985
]
],
[
[
1213,
24,
1598
],
[
1598,
63,
985
]
],
[
[
1213,
64,
1559
],
[
1559,
24,
985
]
],
[
[
1213,
25,
578
],
[
578,
24,
985
]
],
[
[
1213,
25,
710
],
[
710,
63,
985
]
],
[
[
1213,
62,
479
],
[
479,
24,
985
]
]
] | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
]
] | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dasatinib may lead to a major life threatening interaction when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dasatinib may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dasatinib may lead to a major life threatening interaction when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib |
DB00759 | DB13909 | 1,620 | 1,277 | [
"DDInter1783",
"DDInter214"
] | Tetracycline | Bismuth subgallate | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells. The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used. | Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight. It is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter internal deodorant where it is often employed as the primary active ingredient. | Moderate | 1 | [
[
[
1620,
24,
1277
]
],
[
[
1620,
1,
964
],
[
964,
24,
1277
]
],
[
[
1620,
1,
964
],
[
964,
1,
1669
],
[
1669,
24,
1277
]
],
[
[
1620,
1,
1669
],
[
1669,
40,
964
],
[
964,
24,
1277
]
],
[
[
1620,
6,
16560
],
[
16560,
45,
964
],
[
964,
24,
1277
]
],
[
[
1620,
54,
19326
],
[
19326,
15,
964
],
[
964,
24,
1277
]
],
[
[
1620,
23,
1399
],
[
1399,
62,
964
],
[
964,
24,
1277
]
],
[
[
1620,
23,
1399
],
[
1399,
63,
475
],
[
475,
24,
1277
]
],
[
[
1620,
23,
359
],
[
359,
23,
1669
],
[
1669,
24,
1277
]
],
[
[
1620,
23,
1605
],
[
1605,
24,
407
],
[
407,
24,
1277
]
]
] | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Tetracyclines"
],
[
"Tetracyclines",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
]
] | Tetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline (Compound) resembles Minocycline (Compound) and Minocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline (Compound) is included by Tetracyclines (Pharmacologic Class) and Tetracyclines (Pharmacologic Class) includes Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Indapamide and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate |
DB00290 | DB14711 | 329 | 779 | [
"DDInter219",
"DDInter1680"
] | Bleomycin | Smallpox (Vaccinia) Vaccine, Live | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
329,
25,
779
]
],
[
[
329,
64,
1064
],
[
1064,
25,
779
]
],
[
[
329,
25,
1377
],
[
1377,
25,
779
]
],
[
[
329,
24,
147
],
[
147,
25,
779
]
],
[
[
329,
63,
552
],
[
552,
25,
779
]
],
[
[
329,
25,
676
],
[
676,
64,
779
]
],
[
[
329,
64,
1064
],
[
1064,
25,
478
],
[
478,
25,
779
]
],
[
[
329,
25,
1377
],
[
1377,
64,
1064
],
[
1064,
25,
779
]
],
[
[
329,
24,
147
],
[
147,
64,
1064
],
[
1064,
25,
779
]
],
[
[
329,
63,
552
],
[
552,
64,
1064
],
[
1064,
25,
779
]
]
] | [
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
]
] | Bleomycin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live |
DB01619 | DB04844 | 830 | 843 | [
"DDInter1441",
"DDInter1778"
] | Phenindamine | Tetrabenazine | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
830,
24,
843
]
],
[
[
830,
63,
479
],
[
479,
40,
843
]
],
[
[
830,
63,
1594
],
[
1594,
24,
843
]
],
[
[
830,
1,
537
],
[
537,
24,
843
]
],
[
[
830,
24,
849
],
[
849,
63,
843
]
],
[
[
830,
63,
1053
],
[
1053,
25,
843
]
],
[
[
830,
40,
104
],
[
104,
25,
843
]
],
[
[
830,
63,
479
],
[
479,
6,
12523
],
[
12523,
45,
843
]
],
[
[
830,
63,
1594
],
[
1594,
24,
479
],
[
479,
40,
843
]
],
[
[
830,
63,
1376
],
[
1376,
63,
479
],
[
479,
40,
843
]
]
] | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) resembles {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) resembles {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) resembles {v} (Compound)",
"Tetrabenazine"
]
]
] | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Phenindamine (Compound) resembles Cyclizine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Tetrabenazine
Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may lead to a major life threatening interaction when taken with Tetrabenazine
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound) |
DB00563 | DB00631 | 663 | 372 | [
"DDInter1174",
"DDInter405"
] | Methotrexate | Clofarabine | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Moderate | 1 | [
[
[
663,
24,
372
]
],
[
[
663,
64,
1064
],
[
1064,
25,
372
]
],
[
[
663,
5,
11555
],
[
11555,
44,
372
]
],
[
[
663,
6,
17404
],
[
17404,
45,
372
]
],
[
[
663,
7,
7720
],
[
7720,
46,
372
]
],
[
[
663,
18,
2565
],
[
2565,
57,
372
]
],
[
[
663,
7,
4519
],
[
4519,
57,
372
]
],
[
[
663,
21,
29122
],
[
29122,
60,
372
]
],
[
[
663,
63,
1467
],
[
1467,
23,
372
]
],
[
[
663,
24,
255
],
[
255,
62,
372
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"ARL6IP1"
],
[
"ARL6IP1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"HDAC6"
],
[
"HDAC6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clofarabine"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clofarabine"
]
]
] | Methotrexate may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Methotrexate (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Clofarabine (Compound)
Methotrexate (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Clofarabine (Compound)
Methotrexate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Clofarabine (Compound)
Methotrexate (Compound) downregulates ARL6IP1 (Gene) and ARL6IP1 (Gene) is downregulated by Clofarabine (Compound)
Methotrexate (Compound) upregulates HDAC6 (Gene) and HDAC6 (Gene) is downregulated by Clofarabine (Compound)
Methotrexate (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Clofarabine (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine |
DB00994 | DB01327 | 361 | 1,227 | [
"DDInter1277",
"DDInter314"
] | Neomycin | Cefazolin | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin.[A175042,A191529] Neomycin A, or [neamine], is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is | A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. | Moderate | 1 | [
[
[
361,
24,
1227
]
],
[
[
361,
24,
1124
],
[
1124,
40,
1227
]
],
[
[
361,
63,
1087
],
[
1087,
40,
1227
]
],
[
[
361,
63,
277
],
[
277,
1,
1227
]
],
[
[
361,
21,
28722
],
[
28722,
60,
1227
]
],
[
[
361,
24,
1448
],
[
1448,
24,
1227
]
],
[
[
361,
63,
1132
],
[
1132,
24,
1227
]
],
[
[
361,
35,
416
],
[
416,
24,
1227
]
],
[
[
361,
24,
1662
],
[
1662,
63,
1227
]
],
[
[
361,
24,
1124
],
[
1124,
1,
11227
],
[
11227,
40,
1227
]
]
] | [
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
],
[
"Cefamandole",
"{u} (Compound) resembles {v} (Compound)",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotaxime"
],
[
"Cefotaxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefmetazole"
],
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefazolin"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
],
[
"Cefamandole",
"{u} (Compound) resembles {v} (Compound)",
"Cefotiam"
],
[
"Cefotiam",
"{u} (Compound) resembles {v} (Compound)",
"Cefazolin"
]
]
] | Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole and Cefamandole (Compound) resembles Cefazolin (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefotaxime and Cefotaxime (Compound) resembles Cefazolin (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefmetazole and Cefmetazole (Compound) resembles Cefazolin (Compound)
Neomycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Cefazolin (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefazolin
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefazolin
Neomycin (Compound) resembles Kanamycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Cefazolin
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cefazolin
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole and Cefamandole (Compound) resembles Cefotiam (Compound) and Cefotiam (Compound) resembles Cefazolin (Compound) |
DB00013 | DB00975 | 1,255 | 1,317 | [
"DDInter1905",
"DDInter573"
] | Urokinase | Dipyridamole | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
1255,
24,
1317
]
],
[
[
1255,
23,
1631
],
[
1631,
62,
1317
]
],
[
[
1255,
24,
958
],
[
958,
63,
1317
]
],
[
[
1255,
24,
1230
],
[
1230,
24,
1317
]
],
[
[
1255,
64,
942
],
[
942,
24,
1317
]
],
[
[
1255,
25,
126
],
[
126,
24,
1317
]
],
[
[
1255,
25,
330
],
[
330,
64,
1317
]
],
[
[
1255,
25,
1432
],
[
1432,
25,
1317
]
],
[
[
1255,
64,
1578
],
[
1578,
25,
1317
]
],
[
[
1255,
23,
1631
],
[
1631,
62,
1167
],
[
1167,
24,
1317
]
]
] | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
],
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
],
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Streptokinase"
],
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
]
] | Urokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Dipyridamole
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba and Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole
Urokinase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole
Urokinase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole
Urokinase may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may lead to a major life threatening interaction when taken with Dipyridamole
Urokinase may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Dipyridamole
Urokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Dipyridamole
Urokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Streptokinase and Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole |
DB00743 | DB00773 | 808 | 896 | [
"DDInter792",
"DDInter702"
] | Gadobenic acid | Etoposide | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI. Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance. | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Moderate | 1 | [
[
[
808,
24,
896
]
],
[
[
808,
21,
28681
],
[
28681,
60,
896
]
],
[
[
808,
63,
147
],
[
147,
23,
896
]
],
[
[
808,
24,
77
],
[
77,
63,
896
]
],
[
[
808,
63,
322
],
[
322,
24,
896
]
],
[
[
808,
21,
28681
],
[
28681,
60,
945
],
[
945,
62,
896
]
],
[
[
808,
21,
28883
],
[
28883,
60,
11452
],
[
11452,
1,
896
]
],
[
[
808,
21,
28773
],
[
28773,
60,
1176
],
[
1176,
23,
896
]
],
[
[
808,
63,
147
],
[
147,
5,
11659
],
[
11659,
44,
896
]
],
[
[
808,
24,
77
],
[
77,
5,
11555
],
[
11555,
44,
896
]
]
] | [
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Podofilox"
],
[
"Podofilox",
"{u} (Compound) resembles {v} (Compound)",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Urethral disorder"
],
[
"Urethral disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} (Compound) treats {v} (Disease)",
"testicular cancer"
],
[
"testicular cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Etoposide"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Etoposide"
]
]
] | Gadobenic acid (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Gadobenic acid (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Gadobenic acid (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Podofilox (Compound) and Podofilox (Compound) resembles Etoposide (Compound)
Gadobenic acid (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) is treated by Etoposide (Compound)
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Etoposide (Compound) |
DB00443 | DB00624 | 251 | 1,561 | [
"DDInter195",
"DDInter1775"
] | Betamethasone | Testosterone | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935. | Moderate | 1 | [
[
[
251,
24,
1561
]
],
[
[
251,
63,
443
],
[
443,
1,
1561
]
],
[
[
251,
35,
155
],
[
155,
1,
1561
]
],
[
[
251,
24,
1438
],
[
1438,
1,
1561
]
],
[
[
251,
40,
870
],
[
870,
63,
1561
]
],
[
[
251,
24,
1026
],
[
1026,
40,
1561
]
],
[
[
251,
1,
891
],
[
891,
63,
1561
]
],
[
[
251,
40,
1581
],
[
1581,
1,
1561
]
],
[
[
251,
6,
4973
],
[
4973,
45,
1561
]
],
[
[
251,
7,
13230
],
[
13230,
46,
1561
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironolactone"
],
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
],
[
"Fluoxymesterone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Testolactone"
],
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Testosterone"
]
],
[
[
"Betamethasone",
"{u} (Compound) upregulates {v} (Gene)",
"TIPARP"
],
[
"TIPARP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Testosterone"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone (Compound) resembles Testosterone (Compound)
Betamethasone (Compound) resembles Fluoxymesterone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Testosterone (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Testosterone (Compound)
Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Testosterone (Compound)
Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Betamethasone (Compound) resembles Testolactone (Compound) and Testolactone (Compound) resembles Testosterone (Compound)
Betamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Testosterone (Compound)
Betamethasone (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Testosterone (Compound) |
DB00472 | DB06663 | 758 | 1,154 | [
"DDInter758",
"DDInter1398"
] | Fluoxetine | Pasireotide | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
758,
25,
1154
]
],
[
[
758,
63,
1314
],
[
1314,
40,
1154
]
],
[
[
758,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
758,
23,
112
],
[
112,
23,
1154
]
],
[
[
758,
24,
959
],
[
959,
24,
1154
]
],
[
[
758,
24,
1662
],
[
1662,
63,
1154
]
],
[
[
758,
63,
245
],
[
245,
24,
1154
]
],
[
[
758,
64,
702
],
[
702,
25,
1154
]
],
[
[
758,
25,
1011
],
[
1011,
64,
1154
]
],
[
[
758,
63,
322
],
[
322,
25,
1154
]
]
] | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
]
] | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Pasireotide (Compound)
Fluoxetine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Fluoxetine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Pasireotide
Fluoxetine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Pasireotide
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Pasireotide |
DB00480 | DB01098 | 1,668 | 14 | [
"DDInter1035",
"DDInter1622"
] | Lenalidomide | Rosuvastatin | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Rosuvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [simvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] This is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.[A181409,A1793] However, the results of the SATURN trial concluded that despite this difference in potency, there was no difference in their effect on the progression of coronary atherosclerosis. Rosuvastatin is also a unique member of the class of statins due to its high hydrophilicity which increases hepatic uptake at the site of action, low bioavailability, and minimal metabolism via the Cytochrome P450 system. This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4, an enzyme involved in the metabolism of many commonly used drugs. Drugs such as [ciclosporin], [gemfibrozil], and some antiretrovirals are more likely to interact with this statin through antagonism of OATP1B1 organic anion transporter protein 1B1-mediated hepatic uptake of rosuvastatin.[F4649, F4652] | Major | 2 | [
[
[
1668,
25,
14
]
],
[
[
1668,
25,
671
],
[
671,
24,
14
]
],
[
[
1668,
21,
29462
],
[
29462,
60,
14
]
],
[
[
1668,
63,
305
],
[
305,
24,
14
]
],
[
[
1668,
23,
126
],
[
126,
24,
14
]
],
[
[
1668,
24,
1627
],
[
1627,
63,
14
]
],
[
[
1668,
64,
1057
],
[
1057,
24,
14
]
],
[
[
1668,
24,
372
],
[
372,
24,
14
]
],
[
[
1668,
25,
375
],
[
375,
63,
14
]
],
[
[
1668,
1,
770
],
[
770,
24,
14
]
]
] | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Lenalidomide",
"{u} (Compound) resembles {v} (Compound)",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
]
] | Lenalidomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Lenalidomide (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Rosuvastatin (Compound)
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Lenalidomide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Lenalidomide may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Lenalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin |
DB01250 | DB12615 | 712 | 1,381 | [
"DDInter1334",
"DDInter1482"
] | Olsalazine | Plazomicin | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene. Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151] | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases [FDA Label]. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing _Enterobacteriaceae_. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label]. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion. | Moderate | 1 | [
[
[
712,
24,
1381
]
],
[
[
712,
63,
416
],
[
416,
24,
1381
]
],
[
[
712,
24,
123
],
[
123,
24,
1381
]
],
[
[
712,
1,
50
],
[
50,
24,
1381
]
],
[
[
712,
25,
777
],
[
777,
25,
1381
]
],
[
[
712,
63,
1441
],
[
1441,
25,
1381
]
],
[
[
712,
64,
258
],
[
258,
25,
1381
]
],
[
[
712,
63,
416
],
[
416,
62,
608
],
[
608,
23,
1381
]
],
[
[
712,
63,
1272
],
[
1272,
24,
416
],
[
416,
24,
1381
]
],
[
[
712,
24,
123
],
[
123,
63,
416
],
[
416,
24,
1381
]
]
] | [
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
],
[
"Iopromide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
],
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
]
] | Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Olsalazine (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Olsalazine may lead to a major life threatening interaction when taken with Iopromide and Iopromide may lead to a major life threatening interaction when taken with Plazomicin
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin may lead to a major life threatening interaction when taken with Plazomicin
Olsalazine may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol may lead to a major life threatening interaction when taken with Plazomicin
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin |
DB06626 | DB11644 | 263 | 647 | [
"DDInter147",
"DDInter1737"
] | Axitinib | Tafamidis | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations. | Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019. | Moderate | 1 | [
[
[
263,
24,
647
]
],
[
[
263,
63,
1419
],
[
1419,
24,
647
]
],
[
[
263,
63,
1419
],
[
1419,
24,
613
],
[
613,
24,
647
]
],
[
[
263,
64,
307
],
[
307,
62,
1419
],
[
1419,
24,
647
]
],
[
[
263,
63,
1101
],
[
1101,
23,
1419
],
[
1419,
24,
647
]
],
[
[
263,
64,
307
],
[
307,
24,
613
],
[
613,
24,
647
]
],
[
[
263,
63,
1419
],
[
1419,
63,
663
],
[
663,
24,
647
]
],
[
[
263,
24,
1627
],
[
1627,
62,
1419
],
[
1419,
24,
647
]
],
[
[
263,
24,
283
],
[
283,
63,
1419
],
[
1419,
24,
647
]
],
[
[
263,
64,
1622
],
[
1622,
25,
613
],
[
613,
24,
647
]
]
] | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
]
] | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Axitinib may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may lead to a major life threatening interaction when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis |
DB00637 | DB01044 | 1,557 | 246 | [
"DDInter128",
"DDInter809"
] | Astemizole | Gatifloxacin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Major | 2 | [
[
[
1557,
25,
246
]
],
[
[
1557,
64,
1176
],
[
1176,
1,
246
]
],
[
[
1557,
24,
872
],
[
872,
40,
246
]
],
[
[
1557,
18,
10375
],
[
10375,
57,
246
]
],
[
[
1557,
23,
112
],
[
112,
23,
246
]
],
[
[
1557,
24,
603
],
[
603,
63,
246
]
],
[
[
1557,
24,
688
],
[
688,
24,
246
]
],
[
[
1557,
63,
355
],
[
355,
24,
246
]
],
[
[
1557,
24,
51
],
[
51,
25,
246
]
],
[
[
1557,
24,
77
],
[
77,
64,
246
]
]
] | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
]
] | Astemizole may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Gatifloxacin (Compound)
Astemizole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Gatifloxacin (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may lead to a major life threatening interaction when taken with Gatifloxacin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Gatifloxacin |
DB00983 | DB01208 | 480 | 945 | [
"DDInter776",
"DDInter1705"
] | Formoterol | Sparfloxacin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Moderate | 1 | [
[
[
480,
24,
945
]
],
[
[
480,
63,
739
],
[
739,
1,
945
]
],
[
[
480,
24,
1539
],
[
1539,
1,
945
]
],
[
[
480,
21,
30020
],
[
30020,
60,
945
]
],
[
[
480,
24,
1053
],
[
1053,
23,
945
]
],
[
[
480,
24,
1002
],
[
1002,
63,
945
]
],
[
[
480,
24,
688
],
[
688,
24,
945
]
],
[
[
480,
63,
1647
],
[
1647,
24,
945
]
],
[
[
480,
24,
1069
],
[
1069,
64,
945
]
],
[
[
480,
63,
521
],
[
521,
25,
945
]
]
] | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Atrial flutter"
],
[
"Atrial flutter",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
]
] | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin (Compound) resembles Sparfloxacin (Compound)
Formoterol (Compound) causes Atrial flutter (Side Effect) and Atrial flutter (Side Effect) is caused by Sparfloxacin (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Sparfloxacin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Sparfloxacin |
DB01181 | DB11943 | 1,532 | 255 | [
"DDInter906",
"DDInter495"
] | Ifosfamide | Delafloxacin | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. | Minor | 0 | [
[
[
1532,
23,
255
]
],
[
[
1532,
63,
1001
],
[
1001,
23,
255
]
],
[
[
1532,
24,
37
],
[
37,
23,
255
]
],
[
[
1532,
74,
450
],
[
450,
23,
255
]
],
[
[
1532,
24,
913
],
[
913,
24,
255
]
],
[
[
1532,
24,
214
],
[
214,
63,
255
]
],
[
[
1532,
63,
1324
],
[
1324,
24,
255
]
],
[
[
1532,
63,
1411
],
[
1411,
25,
255
]
],
[
[
1532,
25,
497
],
[
497,
25,
255
]
],
[
[
1532,
63,
1001
],
[
1001,
63,
377
],
[
377,
23,
255
]
]
] | [
[
[
"Ifosfamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
]
] | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Ifosfamide (Compound) resembles Cyclophosphamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may lead to a major life threatening interaction when taken with Delafloxacin
Ifosfamide may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Delafloxacin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin |
DB00476 | DB01041 | 109 | 770 | [
"DDInter608",
"DDInter1789"
] | Duloxetine | Thalidomide | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
109,
24,
770
]
],
[
[
109,
6,
7950
],
[
7950,
45,
770
]
],
[
[
109,
21,
29177
],
[
29177,
60,
770
]
],
[
[
109,
24,
849
],
[
849,
63,
770
]
],
[
[
109,
40,
847
],
[
847,
24,
770
]
],
[
[
109,
24,
1614
],
[
1614,
24,
770
]
],
[
[
109,
64,
1494
],
[
1494,
24,
770
]
],
[
[
109,
25,
1264
],
[
1264,
63,
770
]
],
[
[
109,
23,
1559
],
[
1559,
24,
770
]
],
[
[
109,
63,
1424
],
[
1424,
24,
770
]
]
] | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal stiffness"
],
[
"Musculoskeletal stiffness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
]
] | Duloxetine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound)
Duloxetine (Compound) causes Musculoskeletal stiffness (Side Effect) and Musculoskeletal stiffness (Side Effect) is caused by Thalidomide (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Duloxetine (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Duloxetine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Duloxetine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide |
DB00342 | DB04953 | 1,181 | 495 | [
"DDInter1770",
"DDInter708"
] | Terfenadine | Ezogabine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine. | Moderate | 1 | [
[
[
1181,
24,
495
]
],
[
[
1181,
23,
112
],
[
112,
23,
495
]
],
[
[
1181,
24,
1494
],
[
1494,
24,
495
]
],
[
[
1181,
24,
927
],
[
927,
63,
495
]
],
[
[
1181,
25,
1424
],
[
1424,
24,
495
]
],
[
[
1181,
64,
600
],
[
600,
24,
495
]
],
[
[
1181,
25,
1662
],
[
1662,
63,
495
]
],
[
[
1181,
63,
521
],
[
521,
24,
495
]
],
[
[
1181,
25,
478
],
[
478,
25,
495
]
],
[
[
1181,
25,
1593
],
[
1593,
64,
495
]
]
] | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ezogabine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ezogabine"
]
]
] | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ezogabine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Terfenadine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Terfenadine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Terfenadine may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Terfenadine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Ezogabine
Terfenadine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Ezogabine |
DB00773 | DB00995 | 896 | 1,112 | [
"DDInter702",
"DDInter139"
] | Etoposide | Auranofin | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties. | Moderate | 1 | [
[
[
896,
24,
1112
]
],
[
[
896,
7,
2067
],
[
2067,
45,
1112
]
],
[
[
896,
7,
12648
],
[
12648,
46,
1112
]
],
[
[
896,
34,
7720
],
[
7720,
46,
1112
]
],
[
[
896,
18,
1917
],
[
1917,
57,
1112
]
],
[
[
896,
7,
2900
],
[
2900,
57,
1112
]
],
[
[
896,
21,
28826
],
[
28826,
60,
1112
]
],
[
[
896,
24,
36
],
[
36,
63,
1112
]
],
[
[
896,
63,
134
],
[
134,
24,
1112
]
],
[
[
896,
25,
375
],
[
375,
63,
1112
]
]
] | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"IKBKB"
],
[
"IKBKB",
"{u} (Gene) is bound by {v} (Compound)",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"GPER1"
],
[
"GPER1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} (Compound) downregulates {v} (Gene)",
"CDC25B"
],
[
"CDC25B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is downregulated by {v} (Compound)",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
]
] | Etoposide (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Auranofin (Compound)
Etoposide (Compound) upregulates GPER1 (Gene) and GPER1 (Gene) is upregulated by Auranofin (Compound)
Etoposide (Compound) binds PTGS2 (Gene) and Etoposide (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Auranofin (Compound)
Etoposide (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Auranofin (Compound)
Etoposide (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Auranofin (Compound)
Etoposide (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Auranofin (Compound)
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Auranofin
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Auranofin
Etoposide may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Auranofin |
DB06663 | DB08886 | 1,154 | 637 | [
"DDInter1398",
"DDInter126"
] | Pasireotide | Asparaginase Erwinia chrysanthemi | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
1154,
24,
637
]
],
[
[
1154,
64,
392
],
[
392,
24,
637
]
],
[
[
1154,
63,
5
],
[
5,
24,
637
]
],
[
[
1154,
24,
1385
],
[
1385,
63,
637
]
],
[
[
1154,
24,
850
],
[
850,
24,
637
]
],
[
[
1154,
25,
1593
],
[
1593,
24,
637
]
],
[
[
1154,
25,
484
],
[
484,
63,
637
]
],
[
[
1154,
25,
1510
],
[
1510,
25,
637
]
],
[
[
1154,
64,
1377
],
[
1377,
25,
637
]
],
[
[
1154,
63,
770
],
[
770,
25,
637
]
]
] | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Pasireotide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi |
DB09098 | DB11757 | 98 | 960 | [
"DDInter1700",
"DDInter994"
] | Somatrem | Istradefylline | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency. | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019. | Moderate | 1 | [
[
[
98,
24,
960
]
],
[
[
98,
63,
1135
],
[
1135,
23,
960
]
],
[
[
98,
24,
1499
],
[
1499,
24,
960
]
],
[
[
98,
63,
134
],
[
134,
24,
960
]
],
[
[
98,
24,
971
],
[
971,
63,
960
]
],
[
[
98,
63,
384
],
[
384,
25,
960
]
],
[
[
98,
24,
1456
],
[
1456,
25,
960
]
],
[
[
98,
63,
1135
],
[
1135,
24,
1499
],
[
1499,
24,
960
]
],
[
[
98,
24,
1499
],
[
1499,
63,
1135
],
[
1135,
23,
960
]
],
[
[
98,
63,
1419
],
[
1419,
25,
1135
],
[
1135,
23,
960
]
]
] | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Istradefylline"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Istradefylline"
]
]
] | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline |
DB00561 | DB06704 | 1,048 | 247 | [
"DDInter591",
"DDInter952"
] | Doxapram | Iobenguane (I-131) | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
1048,
37,
247
]
],
[
[
1048,
21,
28921
],
[
28921,
60,
247
]
],
[
[
1048,
25,
1161
],
[
1161,
25,
247
]
],
[
[
1048,
24,
1163
],
[
1163,
25,
247
]
],
[
[
1048,
25,
1629
],
[
1629,
64,
247
]
],
[
[
1048,
63,
1290
],
[
1290,
25,
247
]
],
[
[
1048,
64,
534
],
[
534,
25,
247
]
],
[
[
1048,
24,
817
],
[
817,
37,
247
]
],
[
[
1048,
25,
290
],
[
290,
37,
247
]
],
[
[
1048,
63,
1636
],
[
1636,
37,
247
]
]
] | [
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midodrine"
],
[
"Midodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
"Dopamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
]
] | Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Doxapram may lead to a major life threatening interaction when taken with Iobenguane
Doxapram (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Iobenguane (Compound)
Doxapram may lead to a major life threatening interaction when taken with Selegiline and Selegiline may lead to a major life threatening interaction when taken with Iobenguane
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline and Rasagiline may lead to a major life threatening interaction when taken with Iobenguane
Doxapram may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Iobenguane
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Midodrine and Midodrine may lead to a major life threatening interaction when taken with Iobenguane
Doxapram may lead to a major life threatening interaction when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Iobenguane
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Dopamine may lead to a major life threatening interaction when taken with Iobenguane
Doxapram may lead to a major life threatening interaction when taken with Cocaine and Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Cocaine may lead to a major life threatening interaction when taken with Iobenguane
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Phenylephrine may lead to a major life threatening interaction when taken with Iobenguane |
DB01320 | DB12500 | 651 | 283 | [
"DDInter783",
"DDInter714"
] | Fosphenytoin | Fedratinib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
651,
25,
283
]
],
[
[
651,
25,
466
],
[
466,
62,
283
]
],
[
[
651,
25,
351
],
[
351,
23,
283
]
],
[
[
651,
64,
1419
],
[
1419,
24,
283
]
],
[
[
651,
24,
761
],
[
761,
24,
283
]
],
[
[
651,
63,
63
],
[
63,
24,
283
]
],
[
[
651,
25,
436
],
[
436,
24,
283
]
],
[
[
651,
25,
676
],
[
676,
63,
283
]
],
[
[
651,
62,
1347
],
[
1347,
24,
283
]
],
[
[
651,
63,
888
],
[
888,
25,
283
]
]
] | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Artemether"
],
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Fosphenytoin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Fosphenytoin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Fosphenytoin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosphenytoin may lead to a major life threatening interaction when taken with Artemether and Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosphenytoin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib |
DB06228 | DB09068 | 792 | 1,427 | [
"DDInter1609",
"DDInter1948"
] | Rivaroxaban | Vortioxetine | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression. | Moderate | 1 | [
[
[
792,
24,
1427
]
],
[
[
792,
24,
1320
],
[
1320,
63,
1427
]
],
[
[
792,
64,
25
],
[
25,
24,
1427
]
],
[
[
792,
25,
802
],
[
802,
24,
1427
]
],
[
[
792,
25,
1604
],
[
1604,
63,
1427
]
],
[
[
792,
63,
1220
],
[
1220,
24,
1427
]
],
[
[
792,
24,
1670
],
[
1670,
24,
1427
]
],
[
[
792,
63,
1039
],
[
1039,
25,
1427
]
],
[
[
792,
25,
39
],
[
39,
25,
1427
]
],
[
[
792,
24,
1320
],
[
1320,
24,
1017
],
[
1017,
63,
1427
]
]
] | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
]
] | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Rivaroxaban may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Rivaroxaban may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Rivaroxaban may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Vortioxetine
Rivaroxaban may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Vortioxetine
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine |
DB01229 | DB06212 | 973 | 165 | [
"DDInter1378",
"DDInter1833"
] | Paclitaxel (protein-bound) | Tolvaptan | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
973,
24,
165
]
],
[
[
973,
63,
1080
],
[
1080,
1,
165
]
],
[
[
973,
6,
8374
],
[
8374,
45,
165
]
],
[
[
973,
21,
28981
],
[
28981,
60,
165
]
],
[
[
973,
63,
86
],
[
86,
24,
165
]
],
[
[
973,
24,
927
],
[
927,
63,
165
]
],
[
[
973,
64,
1064
],
[
1064,
24,
165
]
],
[
[
973,
24,
478
],
[
478,
24,
165
]
],
[
[
973,
64,
1377
],
[
1377,
25,
165
]
],
[
[
973,
24,
1604
],
[
1604,
64,
165
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} (Compound) resembles {v} (Compound)",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolvaptan"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolvaptan (Compound)
Paclitaxel (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Tolvaptan (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Paclitaxel may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Paclitaxel may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tolvaptan
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Tolvaptan |
DB00475 | DB06282 | 1,119 | 516 | [
"DDInter355",
"DDInter1053"
] | Chlordiazepoxide | Levocetirizine | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1119,
24,
516
]
],
[
[
1119,
62,
1031
],
[
1031,
23,
516
]
],
[
[
1119,
24,
1074
],
[
1074,
63,
516
]
],
[
[
1119,
63,
701
],
[
701,
24,
516
]
],
[
[
1119,
24,
1614
],
[
1614,
24,
516
]
],
[
[
1119,
40,
1174
],
[
1174,
24,
516
]
],
[
[
1119,
1,
523
],
[
523,
24,
516
]
],
[
[
1119,
64,
475
],
[
475,
24,
516
]
],
[
[
1119,
62,
1031
],
[
1031,
24,
697
],
[
697,
24,
516
]
],
[
[
1119,
24,
1074
],
[
1074,
63,
701
],
[
701,
24,
516
]
]
] | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
],
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Temazepam"
],
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
],
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
]
] | Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Chlordiazepoxide (Compound) resembles Temazepam (Compound) and Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Chlordiazepoxide (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Chlordiazepoxide may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine |
DB00218 | DB01169 | 1,176 | 57 | [
"DDInter1247",
"DDInter120"
] | Moxifloxacin | Arsenic trioxide | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Major | 2 | [
[
[
1176,
25,
57
]
],
[
[
1176,
23,
112
],
[
112,
23,
57
]
],
[
[
1176,
24,
603
],
[
603,
63,
57
]
],
[
[
1176,
24,
480
],
[
480,
24,
57
]
],
[
[
1176,
25,
1616
],
[
1616,
64,
57
]
],
[
[
1176,
1,
246
],
[
246,
25,
57
]
],
[
[
1176,
25,
167
],
[
167,
25,
57
]
],
[
[
1176,
1,
945
],
[
945,
64,
57
]
],
[
[
1176,
64,
600
],
[
600,
25,
57
]
],
[
[
1176,
23,
589
],
[
589,
25,
57
]
]
] | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
]
] | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Moxifloxacin may lead to a major life threatening interaction when taken with Histrelin and Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Moxifloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Arsenic trioxide
Moxifloxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may lead to a major life threatening interaction when taken with Arsenic trioxide
Moxifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Arsenic trioxide
Moxifloxacin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Arsenic trioxide
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Arsenic trioxide |
DB00912 | DB12332 | 473 | 1,619 | [
"DDInter1581",
"DDInter1626"
] | Repaglinide | Rucaparib | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
473,
24,
1619
]
],
[
[
473,
24,
222
],
[
222,
23,
1619
]
],
[
[
473,
63,
307
],
[
307,
23,
1619
]
],
[
[
473,
24,
154
],
[
154,
24,
1619
]
],
[
[
473,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
473,
25,
739
],
[
739,
24,
1619
]
],
[
[
473,
24,
1501
],
[
1501,
63,
1619
]
],
[
[
473,
24,
1163
],
[
1163,
25,
1619
]
],
[
[
473,
24,
1339
],
[
1339,
64,
1619
]
],
[
[
473,
25,
246
],
[
246,
25,
1619
]
]
] | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
]
] | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Repaglinide may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline and Rasagiline may lead to a major life threatening interaction when taken with Rucaparib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotralstat may lead to a major life threatening interaction when taken with Rucaparib
Repaglinide may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Rucaparib |
DB00734 | DB01409 | 1,664 | 1,415 | [
"DDInter1605",
"DDInter1815"
] | Risperidone | Tiotropium | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. Tiotropium was granted FDA approval on 30 January 2004. | Moderate | 1 | [
[
[
1664,
24,
1415
]
],
[
[
1664,
6,
8374
],
[
8374,
45,
1415
]
],
[
[
1664,
21,
29022
],
[
29022,
60,
1415
]
],
[
[
1664,
62,
752
],
[
752,
23,
1415
]
],
[
[
1664,
63,
1594
],
[
1594,
24,
1415
]
],
[
[
1664,
24,
1264
],
[
1264,
24,
1415
]
],
[
[
1664,
24,
830
],
[
830,
63,
1415
]
],
[
[
1664,
24,
1429
],
[
1429,
74,
1415
]
],
[
[
1664,
6,
8374
],
[
8374,
45,
752
],
[
752,
23,
1415
]
],
[
[
1664,
21,
29022
],
[
29022,
60,
673
],
[
673,
24,
1415
]
]
] | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Joint swelling"
],
[
"Joint swelling",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
],
[
"Aclidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tiotropium"
]
],
[
[
"Risperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Joint swelling"
],
[
"Joint swelling",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
]
] | Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tiotropium (Compound)
Risperidone (Compound) causes Joint swelling (Side Effect) and Joint swelling (Side Effect) is caused by Tiotropium (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Tiotropium
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium (Compound) resembles Tiotropium (Compound) and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Tiotropium
Risperidone (Compound) causes Joint swelling (Side Effect) and Joint swelling (Side Effect) is caused by Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium |
DB00448 | DB01172 | 1,215 | 416 | [
"DDInter1022",
"DDInter1004"
] | Lansoprazole | Kanamycin | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
1215,
24,
416
]
],
[
[
1215,
21,
29196
],
[
29196,
60,
416
]
],
[
[
1215,
63,
1252
],
[
1252,
23,
416
]
],
[
[
1215,
24,
1381
],
[
1381,
63,
416
]
],
[
[
1215,
40,
837
],
[
837,
24,
416
]
],
[
[
1215,
25,
663
],
[
663,
24,
416
]
],
[
[
1215,
24,
955
],
[
955,
24,
416
]
],
[
[
1215,
23,
1004
],
[
1004,
63,
416
]
],
[
[
1215,
23,
1479
],
[
1479,
24,
416
]
],
[
[
1215,
24,
1680
],
[
1680,
25,
416
]
]
] | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
],
[
"Plazomicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
]
] | Lansoprazole (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Kanamycin (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Lansoprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Lansoprazole may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may lead to a major life threatening interaction when taken with Kanamycin |
DB00163 | DB00773 | 1,461 | 896 | [
"DDInter1943",
"DDInter702"
] | Vitamin E | Etoposide | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Moderate | 1 | [
[
[
1461,
24,
896
]
],
[
[
1461,
6,
1826
],
[
1826,
45,
896
]
],
[
[
1461,
24,
147
],
[
147,
23,
896
]
],
[
[
1461,
62,
58
],
[
58,
24,
896
]
],
[
[
1461,
24,
310
],
[
310,
63,
896
]
],
[
[
1461,
24,
322
],
[
322,
24,
896
]
],
[
[
1461,
23,
1531
],
[
1531,
63,
896
]
],
[
[
1461,
62,
1057
],
[
1057,
25,
896
]
],
[
[
1461,
23,
375
],
[
375,
64,
896
]
],
[
[
1461,
24,
1064
],
[
1064,
25,
896
]
]
] | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} (Compound) binds {v} (Gene)",
"GSTP1"
],
[
"GSTP1",
"{u} (Gene) is bound by {v} (Compound)",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
]
] | Vitamin E (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Etoposide (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Etoposide
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Etoposide
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Etoposide |
DB00549 | DB00673 | 522 | 723 | [
"DDInter1955",
"DDInter112"
] | Zafirlukast | Aprepitant | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Moderate | 1 | [
[
[
522,
24,
723
]
],
[
[
522,
24,
875
],
[
875,
40,
723
]
],
[
[
522,
6,
7950
],
[
7950,
45,
723
]
],
[
[
522,
21,
28750
],
[
28750,
60,
723
]
],
[
[
522,
24,
1627
],
[
1627,
62,
723
]
],
[
[
522,
23,
479
],
[
479,
62,
723
]
],
[
[
522,
62,
1230
],
[
1230,
23,
723
]
],
[
[
522,
63,
11
],
[
11,
24,
723
]
],
[
[
522,
24,
214
],
[
214,
63,
723
]
],
[
[
522,
24,
311
],
[
311,
24,
723
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} (Compound) resembles {v} (Compound)",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal discomfort"
],
[
"Abdominal discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
],
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
]
] | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Zafirlukast (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Zafirlukast (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Aprepitant (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant |
DB00176 | DB08901 | 529 | 1,468 | [
"DDInter770",
"DDInter1492"
] | Fluvoxamine | Ponatinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
529,
24,
1468
]
],
[
[
529,
24,
478
],
[
478,
24,
1468
]
],
[
[
529,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
529,
18,
6717
],
[
6717,
46,
1468
]
],
[
[
529,
7,
3466
],
[
3466,
46,
1468
]
],
[
[
529,
18,
3741
],
[
3741,
57,
1468
]
],
[
[
529,
21,
29271
],
[
29271,
60,
1468
]
],
[
[
529,
24,
1215
],
[
1215,
23,
1468
]
],
[
[
529,
23,
1135
],
[
1135,
62,
1468
]
],
[
[
529,
24,
1362
],
[
1362,
63,
1468
]
]
] | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) downregulates {v} (Gene)",
"HERPUD1"
],
[
"HERPUD1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) upregulates {v} (Gene)",
"CCNA1"
],
[
"CCNA1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) downregulates {v} (Gene)",
"OXA1L"
],
[
"OXA1L",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Migraine"
],
[
"Migraine",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
]
] | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Fluvoxamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Ponatinib (Compound)
Fluvoxamine (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Ponatinib (Compound)
Fluvoxamine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound)
Fluvoxamine (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB00352 | DB11988 | 482 | 270 | [
"DDInter1814",
"DDInter1321"
] | Tioguanine | Ocrelizumab | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Moderate | 1 | [
[
[
482,
24,
270
]
],
[
[
482,
63,
1461
],
[
1461,
23,
270
]
],
[
[
482,
24,
134
],
[
134,
24,
270
]
],
[
[
482,
24,
287
],
[
287,
63,
270
]
],
[
[
482,
63,
66
],
[
66,
24,
270
]
],
[
[
482,
25,
770
],
[
770,
24,
270
]
],
[
[
482,
35,
328
],
[
328,
24,
270
]
],
[
[
482,
25,
962
],
[
962,
25,
270
]
],
[
[
482,
25,
676
],
[
676,
64,
270
]
],
[
[
482,
64,
1066
],
[
1066,
25,
270
]
]
] | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
],
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
]
] | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Tioguanine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Tioguanine may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab
Tioguanine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Tioguanine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Ocrelizumab |
DB00555 | DB00650 | 706 | 1,147 | [
"DDInter1020",
"DDInter1041"
] | Lamotrigine | Leucovorin | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850] | Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. Despite this difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side effects (Kovoor et al, 2009). As folate analogs, leucovorin and levoleucovorin are both used to counteract the toxic effects of folic acid antagonists, such as methotrexate, which act by inhibiting the enzyme dihydrofolate reductase (DHFR). They are indicated for use as rescue therapy following use of high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Injectable forms are also indicated for use in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects associated with methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects. | Moderate | 1 | [
[
[
706,
24,
1147
]
],
[
[
706,
63,
356
],
[
356,
1,
1147
]
],
[
[
706,
21,
28929
],
[
28929,
60,
1147
]
],
[
[
706,
23,
663
],
[
663,
35,
1147
]
],
[
[
706,
63,
356
],
[
356,
1,
11782
],
[
11782,
40,
1147
]
],
[
[
706,
21,
28929
],
[
28929,
60,
356
],
[
356,
1,
1147
]
],
[
[
706,
21,
28714
],
[
28714,
60,
11782
],
[
11782,
40,
1147
]
],
[
[
706,
21,
28987
],
[
28987,
60,
651
],
[
651,
63,
1147
]
],
[
[
706,
23,
663
],
[
663,
1,
11782
],
[
11782,
40,
1147
]
],
[
[
706,
63,
356
],
[
356,
40,
11343
],
[
11343,
1,
1147
]
]
] | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Folic acid"
],
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Folic acid"
],
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Raltitrexed"
],
[
"Raltitrexed",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Folic acid"
],
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Raltitrexed"
],
[
"Raltitrexed",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} (Compound) resembles {v} (Compound)",
"Raltitrexed"
],
[
"Raltitrexed",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Folic acid"
],
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Tetrahydrofolic acid"
],
[
"Tetrahydrofolic acid",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
]
]
] | Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Folic acid and Folic acid (Compound) resembles Leucovorin (Compound)
Lamotrigine (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Leucovorin (Compound)
Lamotrigine may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate (Compound) resembles Leucovorin (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Leucovorin
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Folic acid and Folic acid (Compound) resembles Raltitrexed (Compound) and Raltitrexed (Compound) resembles Leucovorin (Compound)
Lamotrigine (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Folic acid (Compound) and Folic acid (Compound) resembles Leucovorin (Compound)
Lamotrigine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Raltitrexed (Compound) and Raltitrexed (Compound) resembles Leucovorin (Compound)
Lamotrigine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Fosphenytoin (Compound) and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Leucovorin
Lamotrigine may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate (Compound) resembles Raltitrexed (Compound) and Raltitrexed (Compound) resembles Leucovorin (Compound)
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Folic acid and Folic acid (Compound) resembles Tetrahydrofolic acid (Compound) and Tetrahydrofolic acid (Compound) resembles Leucovorin (Compound) |
DB00741 | DB01183 | 167 | 173 | [
"DDInter885",
"DDInter1262"
] | Hydrocortisone | Naloxone | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors. When taken in large quantities, opioid medications such as [morphine], [hydromorphone], [methadone], [heroin], or [fentanyl] are capable of causing life-threatening symptoms such as respiratory depression, reduced heart rate, slurred speech, drowsiness, and constricted pupils.[A234594,L33724] If untreated, this can progress to vomiting, absent pulse and breathing, loss of consciousness, and even death. Naloxone is indicated for the rapid reversal of these symptoms of central nervous system depression in opioid overdose. It's important to note that naloxone only works on opioid receptors within the body, and is therefore not capable of reversing the effects of non-opioid medications such as stimulants like [methamphetamine] or [cocaine], or benzodiazepines like [lorazepam] or [diazepam]. Also known as the brand name product Narcan, naloxone is currently available by intramuscular (IM) or subcutaneous (SubQ) injection, nasal spray, or intravenous (IV) infusion.[L33729,L33739] Naloxone IM injections are commonly available in the form of "kits", which is ideal for making overdose treatment accessible and readily available for administration by minimally trained individuals within the community. Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. Frequently also carried by medical and emergency personnel and at events known to be associated with heavy drug use like music festivals, naloxone kits are considered a key component of harm reduction strategies. There are over-the-counter nasal sprays available. When injected intramuscularly (IM), naloxone acts within three to five minutes. Administration of naloxone is associated with very few side effects. Notably, if injected into a person not currently using opioid medications, there would be no noticeable effects at all. However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal symptoms. Common symptoms of opioid withdrawal include nausea, vomiting, sweating, runny nose, aches, and diarrhea. Although certainly physically uncomfortable, opioid withdrawal symptoms are not life-threatening; administration of naloxone is, therefore, appropriate for any person appearing to have any symptoms of an opioid overdose. Due to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. Naloxone is also available within the combination product Suboxone with the opioid medication [buprenorphine].[L33714,L33719] Suboxone is used for the maintenance treatment of opioid dependence and addiction.[L33714,L33719] When taken orally, naloxone has no pharmacological effect and does not reduce the effectiveness of the opioid effect of buprenorphine.[L33714,L33719] The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.[L33714,L33719] Naloxone was granted FDA approval on 13 April 1971. | Minor | 0 | [
[
[
167,
23,
173
]
],
[
[
167,
6,
4973
],
[
4973,
45,
173
]
],
[
[
167,
21,
28882
],
[
28882,
60,
173
]
],
[
[
167,
64,
78
],
[
78,
25,
173
]
],
[
[
167,
6,
4973
],
[
4973,
45,
509
],
[
509,
40,
173
]
],
[
[
167,
21,
28882
],
[
28882,
60,
314
],
[
314,
24,
173
]
],
[
[
167,
21,
28792
],
[
28792,
60,
1235
],
[
1235,
40,
173
]
],
[
[
167,
18,
18226
],
[
18226,
57,
314
],
[
314,
24,
173
]
],
[
[
167,
64,
78
],
[
78,
64,
475
],
[
475,
24,
173
]
],
[
[
167,
6,
4973
],
[
4973,
45,
475
],
[
475,
24,
173
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} (Compound) resembles {v} (Compound)",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} (Compound) resembles {v} (Compound)",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
]
] | Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naloxone (Compound)
Hydrocortisone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Naloxone (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Droperidol and Droperidol may lead to a major life threatening interaction when taken with Naloxone
Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Buprenorphine (Compound) and Buprenorphine (Compound) resembles Naloxone (Compound)
Hydrocortisone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Hydrocortisone (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Hydrocodone (Compound) and Hydrocodone (Compound) resembles Naloxone (Compound)
Hydrocortisone (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Hydrocortisone may lead to a major life threatening interaction when taken with Droperidol and Droperidol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.